[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 157
1. Abdel Hamid TM, El Zawahry HM, Khattab NA, Mowafy TM, Awaad MM, Ali El-Din NH, Mokhtar NM: Prognostic factors of Hodgkin's lymphoma and their impact on response to chemotherapy and survival. J Egypt Natl Canc Inst; 2005 Mar;17(1):9-14
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of Hodgkin's lymphoma and their impact on response to chemotherapy and survival.
  • OBJECTIVE: The aim of this study was to compare the standard prognostic factors of Hodgkin's lymphoma (HL) in relation to response to first line chemotherapy, disease free survival (DFS) and overall survival (OS).
  • PATIENTS AND METHODS: The study was performed on a group of 100 adult patients diagnosed as HL and who were treated and followed-up in the years 1999 to 2001, in the Medical Oncology Department at National Cancer Institute (NCI), Cairo.
  • The first line chemotherapy was COPP in 40%, ABVD in 35% and COPP/ABV hybrid in 25%.
  • Patients were classified into early stage disease: Stages I, IIA and IIB without poor risk factors, n=43 and advanced stage disease: Stages III, IV and IIB with poor risk factors, n=57 analysis of the prognostic factors for early versus advanced-stage disease was done by univariate and multivariate regression analysis.
  • RESULTS: Complete remission (CR) was attained in 69% of the patients after first line chemotherapy; being 87.8 % and 54.7% for early and advanced disease, respectively, (p=0.0001).
  • The CR rates after different chemotherapy regimens were 81.8%, 90% and 90% for the ABVD, COPP and COPP/ABV hybrid regimens in the early-disease group; respectively; in contrast to the corresponding figures of 54.5%, 50% and 61.5% in the advanced- stage group.
  • The DFS and OS in this series of patients were 61.3% and 53.7%, being 69.8% and 70.7% for the early and 45.1% and 38.9% for the advanced-disease, respectively The OS of the whole group was significantly related to age (p=0.04), sex (p=0.005), early versus advanced disease (p=0.0001) and B symptoms (p=0.0006).
  • CONCLUSIONS: The adequate response and DFS of the early compared to the advanced-stage disease supported the evolving role of risk adapted chemotherapy for HL.
  • The results of this study pointed to the need for an improved treatment strategy in this potentially curable disease,especially for the advanced disease.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Sex Factors. Survival. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353077.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Gobbi PG, Broglia C, Bertè R, Petrilli MP, Molica S, Angrilli F, Iannitto E, Ghirardelli ML, Di Renzo N, Cavanna L, Ascari E: Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease. Haematologica; 2000 Jul;85(7):722-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
  • BACKGROUND AND OBJECTIVES: To evaluate the feasibility, toxicity and preliminary results of a potentially less toxic variant of the MOPPEBVCAD chemotherapy regimen for advanced Hodgkin's disease: MOPPEBVCyED, in which cyclophosphamide and etoposide replace lomustine and melphalan, respectively, with the remaining components being unaltered.
  • DESIGN AND METHODS: The study was multicenter, prospective and randomized, and enrolled 67 patients with newly diagnosed stage IIB, III, IV Hodgkin's disease (62 were expected on the grounds of statistical considerations).
  • Radiotherapy was restricted to sites of bulky involvement or to areas that responded incompletely to chemotherapy.
  • RESULTS: Comparing MOPPEBVCAD vs. MOPPEBVCyED, the results were as follows: complete remissions 35/35 vs. 30/32 (plus one partial remission and one disease progression); relapses 5 vs. 8; deaths 2 (one of myelodysplasia) vs. 2; delivered mean dose intensity (DI): lomustine 0.79+/-0.67 vs. cyclophosphamide 0.82+/-0.32; melphalan 0.80+/-0.13 vs. etoposide 0.86+/-0.18; average DI of the 7 drugs common to both regimens 0.73+/-0.10 vs. 0.83+/-0.11; all 9 drugs 0.75+/-0.13 vs. 0.84+/-0.09 (p=0.002); projected 5-year failure-free survival 0.79 vs 0.62; second cancers, two myelodysplasias vs. one carcinoma of the kidney.
  • INTERPRETATION AND CONCLUSIONS: The higher cumulative and single drug DI recorded with MOPPEBVCyED may reflect better short-term tolerability, but it does not lead to better disease control.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / standards. Bleomycin / toxicity. Epirubicin / administration & dosage. Epirubicin / standards. Epirubicin / toxicity. Female. Humans. Lomustine / administration & dosage. Lomustine / standards. Lomustine / toxicity. Male. Mechlorethamine / administration & dosage. Mechlorethamine / standards. Mechlorethamine / toxicity. Melphalan / administration & dosage. Melphalan / standards. Melphalan / toxicity. Middle Aged. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Procarbazine / administration & dosage. Procarbazine / standards. Procarbazine / toxicity. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / standards. Vinblastine / toxicity. Vincristine / administration & dosage. Vincristine / standards. Vincristine / toxicity. Vindesine / administration & dosage. Vindesine / standards. Vindesine / toxicity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10897124.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] ITALY
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 3Z8479ZZ5X / Epirubicin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; CAD protocol 1; EBV protocol; MOPP protocol
  •  go-up   go-down


3. Lishner M, Koren G: Cancer chemotherapy during pregnancy. Consortium of cancer in pregnancy evidence. Can Fam Physician; 2001 Jan;47:41-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer chemotherapy during pregnancy. Consortium of cancer in pregnancy evidence.
  • QUESTION: I have an 8-weeks' pregnant patient who was diagnosed with stage III Hodgkin's disease last week.
  • The oncologist suggests delaying chemotherapy until the second trimester.
  • What are the effects of chemotherapy on a fetus after the first trimester?
  • ANSWER: Available data suggest that exposure to chemotherapy during the first trimester of pregnancy is associated with increased risk of major malformations.
  • [MeSH-major] Abnormalities, Drug-Induced. Antineoplastic Agents / adverse effects. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Brain / abnormalities. Brain / embryology. Female. Hodgkin Disease / drug therapy. Humans. Pregnancy. Pregnancy Trimester, First. Risk Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pregnancy and Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Obstet Gynaecol Br Commonw. 1968 Mar;75(3):307-12 [4868587.001]
  • [Cites] Am J Med. 1980 Dec;69(6):828-32 [7446548.001]
  • [Cites] Cancer Treat Rep. 1985 Dec;69(12):1387-89 [4075315.001]
  • [Cites] Clin Invest Med. 1985;8(4):333-8 [4075619.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2058-64 [3046546.001]
  • [Cites] Lancet. 1989 Mar 4;1(8636):497 [2563865.001]
  • [Cites] J Am Med Assoc. 1960 Apr 16;172:1765-71 [13832514.001]
  • [Cites] Am J Hematol. 1991 Apr;36(4):243-8 [1707227.001]
  • [Cites] Arch Intern Med. 1992 Mar;152(3):573-6 [1546920.001]
  • [Cites] Teratog Carcinog Mutagen. 1993;13(3):139-43 [8105555.001]
  • [Cites] Obstet Gynecol Surv. 1996 Feb;51(2):125-34 [8622836.001]
  • [Cites] Pharmacol Ther. 1997;74(2):207-20 [9336023.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):855-61 [10071276.001]
  • [Cites] Obstet Gynecol Surv. 1990 Aug;45(8):509-14 [2198503.001]
  • (PMID = 11212430.001).
  • [ISSN] 0008-350X
  • [Journal-full-title] Canadian family physician Médecin de famille canadien
  • [ISO-abbreviation] Can Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2014699
  •  go-up   go-down


Advertisement
4. Anselmo AP, Cavalieri E, Osti FM, Cantonetti M, De Sanctis V, Alfo M, Amadori S, Enrici RM: Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. Anticancer Res; 2004 Nov-Dec;24(6):4045-50
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
  • BACKGROUND: To improve long-term survival by reducing toxicity in intermediate stage Hodgkin's disease patients, we compared the effects of involved field (IF) versus extended field (EF) irradiation administered after four cycles of ABVD regimen.
  • MATERIALS AND METHODS: Two hundred and ten Hodgkin's disease patients, at clinical stage II with risk factors and III without risk factors, were enrolled in the randomized study HD94.
  • CONCLUSION: We confirm the efficacy of four cycles of ABVD regimen, with suitable dose intensity, and radiotherapy as consolidation therapy, in intermediate stage Hodgkin's disease patients (CR = 99.5% and OS = 95%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Risk Factors. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736450.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


5. El Helw LM, Lorigan PC, Robinson MH, Coleman RE, Hancock BW: VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma. Int J Oncol; 2000 Apr;16(4):777-82
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.
  • An evaluation was carried out of the efficacy and toxicity of a novel weekly palliative chemotherapy regimen comprising vincristine, epirubicin and dexamethasone (VEDex) in 57 patients with non-Hodgkin's lymphoma (NHL) treated at this centre.
  • Twenty-three patients (40%) had low grade disease and 4 patients (7%) had transformed NHL.
  • Thirty patients (53%) had high grade NHL; 7 had relapsed after conventional chemotherapy and were not fit for high-dose chemotherapy, 7 were heavily pre-treated, 8 had received prior radiotherapy and 8 had not received any prior therapy.
  • Responding patients received a total of 8 weeks of treatment, but treatment could be repeated at a later stage if required.
  • A further 11 patients (19.3%) had stable disease.
  • The median survival from the onset of treatment was 6 months.
  • Grade III neutropenia was seen in 9 patients (15.8%).
  • Other toxicity included nausea and vomiting grade II (3.5%), grade III (1.8%) and alopecia grade III (1.8%).
  • There were no treatment related deaths.
  • We conclude that VEDex is an effective palliative treatment in patients with indolent or aggressive lymphoma with poor performance status or who have been heavily pre-treated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Palliative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dexamethasone / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10717248.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


6. Huang HQ, Jiang WQ, Wang W, Xu GC, Zhang L, He YJ, Sun XF, Zhou ZM, Liu DG, Xu RH, Lin TY, Teng XY, Liu MZ, Su YS, Li YH, Lin XB, Guan ZZ: [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality]. Ai Zheng; 2002 Dec;21(12):1345-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality].
  • BACKGROUND & OBJECTIVE: Hodgkin's disease (HD) is a chemo- and radio-sensitive hematologic malignancy.
  • At present, improvement of cure rate, reduction of long-term toxicity, and maintenance of good quality of life are the major issues in the treatment of HD.
  • METHODS: The results of 295 patients with histology-proven HD from 1970 to 2000, especially from 1980 to 2000 were analyzed.
  • RESULTS: A total of 295 HD patients were treated by chemotherapy-predominant comprehensive modality.
  • The 5, 10, and 20 years overall survival for 295 HD patients were 63.5%, 55.8%, and 47.1%, respectively, with median survival time of 172.3 months (28-351.9 months) at the median follow-up time of 42.9 months (17-351.9 months).
  • The 5, 10, and 20 years overall survival and disease-free survival were 79.6%, 74.5%, and 66.8% as well as 74.5%, 69.4%, and 69.4% respectively for the patients treated with regular chemotherapy and radiotherapy from 1980 to 2000.
  • Multivariate analysis demonstrated that age over 45-year-old, B symptoms and stage III/IV were the main prognostic factors (P = 0.000, P = 0.035, and P = 0.047) in this clinical study.
  • The prognosis of the patients with stage I/II and nodular sclerosis was better in comparison to stages III/IV and other histologic subtypes.
  • CONCLUSIONS: Chemotherapy-predominant combined with involved fields irradiation play an important role in HD treatment with promising long term survival and lower late toxicities.
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Clinical Trials as Topic. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Villani F, Fede Catania A, Laffranchi A, Maffioli L, Viviani S, Bonfante V: Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease. Cancer Invest; 2003 Apr;21(2):185-92
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease.
  • Mediastinal irradiation combined with chemotherapy in patients with Hodgkin's disease have been associated with cardiopulmonary toxic effects that can last over the years.
  • In this study we monitored pulmonary and cardiac function in 39 patients affected by advanced Hodgkin's disease (stage II B-III and IV) with mediastinal involvement and submitted to an intensive chemotherapy regimen (epirubicin, vincristine, ciclophosphamide, and etoposide) followed by involved field irradiation.
  • Spirometric parameters did no show modifications at the end of treatment, on the contrary they improved during the follow-up.
  • DLCO remained constantly decreased. sEKG did not show significant modification, whereas LVEF significantly decreased at the end of treatment and remained persistently decreased during follow-up.
  • One patient, 49 years old, suffered from myocardial infarction 25 months after the completion of radio-chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy / adverse effects. Cyclophosphamide / administration & dosage. Electrocardiography / drug effects. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Heart / drug effects. Heart Function Tests. Humans. Lung / drug effects. Male. Middle Aged. Radiotherapy Dosage. Respiratory Function Tests. Retrospective Studies. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12743983.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


8. Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E: A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Haematologica; 2000 Mar;85(3):263-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
  • BACKGROUND AND OBJECTIVE: The positive results of high-dose chemotherapy followed by rescue with bone marrow progenitor cell transplantation are generally ascribed to the high dose size (DS) of the drugs given.
  • With the aim of comparing the role of DS and DI in non-Hodgkin's lymphomas, a variant of Fisher's ProMACE-CytaBOM regimen was designed in which the projected cumulative drug DIs remained the same as in the original schedule but the DSs were tripled.
  • Thirty-six outpatients with intermediate- and high-grade non-Hodgkin's lymphomas entered the pilot study; 29 were untreated and 7 had relapse disease.
  • Clinical stage was I in 1 patient, II in 7, III in 5 and IV in 23; 10 had B symptoms; the IPI score was 0-2 in 29 cases and > or =3 in the remaining 7.
  • RESULTS: Of the 29 previously untreated patients, 16 achieved complete remission, 8 partial remission, 4 developed progressive disease and 1 was withdrawn early from the study because of acute viral hepatitis; subsequently 4 relapsed and 3 died (2 of disease progression, 1 of causes unrelated to the disease).
  • In the pre-treated group 3 patients obtained complete remission, 2 partial remission and in 1 patient the disease progressed; 3 of these pre-treated patients died (1 of progressive disease, 1 of a new relapse, 1 of myocardial infarction during therapy).
  • Limited use of G-CSF is required (about 3 vials after each drug administration).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Anemia / chemically induced. Bleomycin / administration & dosage. Bleomycin / toxicity. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Cytarabine / administration & dosage. Cytarabine / toxicity. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Etoposide / administration & dosage. Etoposide / toxicity. Female. Humans. Italy. Male. Methotrexate / administration & dosage. Methotrexate / toxicity. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Prednisone / toxicity. Recurrence. Survival Rate. Vincristine / administration & dosage. Vincristine / toxicity

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10702814.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; PROMACE-CytaBOM protocol
  •  go-up   go-down


9. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD: Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys; 2003 Jan 1;55(1):36-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
  • PURPOSE: We analyzed in-field (IF) control in adults with early-stage Hodgkin's disease who received chemotherapy followed by radiotherapy (RT) in terms of the (1) chemotherapeutic regimen used and number of cycles delivered, (2) response to chemotherapy, and (3) initial tumor size.
  • METHODS AND MATERIALS: From 1980 to 1995, 286 patients ranging in age from 16 to 88 years (median: 28 years) with Ann Arbor clinical Stage I or II Hodgkin's disease underwent chemotherapy followed 3 to 4 weeks later by RT.
  • There were 516 nodal sites measuring 0.5 to 19.0 cm at the start of chemotherapy, including 134 cases of bulky mediastinal disease.
  • Patients received 1-8 (median: 3) cycles of induction chemotherapy.
  • All 533 gross nodal and extranodal sites of disease were included in the RT fields.
  • The median prescribed RT dose for gross disease was 40.0 Gy given in 20 daily 2.0-Gy fractions.
  • The chemotherapeutic regimen used and the number of cycles of chemotherapy delivered did not significantly affect IF control.
  • IF control also did not significantly depend on the response to induction chemotherapy.
  • In cases where there was a confirmed or unconfirmed complete response as opposed to a partial response or stable disease in response to induction chemotherapy for bulky nodal disease, the 5-year IF control rates were 99% and 92%, respectively (p = 0.0006).
  • The 15-year actuarial risks of coronary artery disease requiring surgical intervention and of solid tumors were 4.1% and 16.8%, respectively.
  • CONCLUSIONS: In patients with nonbulky disease, induction chemotherapy followed by RT to a median dose of 40.0 Gy resulted in excellent IF control, regardless of the chemotherapeutic regimen used, the fact that only 1-2 cycles of chemotherapy were delivered, and the response to chemotherapy.
  • Ongoing Phase III trials will help clarify whether lower RT doses and smaller RT fields after chemotherapy can maintain the IF control seen in our study, but with a lower incidence of late complications in patients with Stage I or II Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Heart / drug effects. Heart / radiation effects. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504034.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


10. Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ: Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol; 2007 Sep 1;25(25):3902-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
  • PURPOSE: To correlate [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) status after chemotherapy, but before radiation, with outcome in patients treated with the Stanford V regimen.
  • PATIENTS AND METHODS: We analyzed retrospectively 81 patients with Hodgkin's disease who had serial [(18)F]FDG-PET scans performed at baseline and again at the completion of Stanford V chemotherapy, before planned radiotherapy.
  • Patients with favorable stage I/II (nonbulky mediastinal disease) and those with bulky mediastinal disease or stage III/IV were scanned after 8 and 12 weeks of chemotherapy, respectively.
  • Radiotherapy fields were determined before starting chemotherapy based on baseline computed tomography scans.
  • RESULTS: After chemotherapy, six of 81 patients had residual [(18)F]FDG-PET-positive sites, all in sites for which radiotherapy was planned.
  • Four of the six patients with positive [(18)F]FDG-PET scans after chemotherapy experienced relapse compared with just three of 75 patients with negative [(18)F]FDG-PET scans.
  • In a bivariate Cox model, [(18)F]FDG-PET positivity after chemotherapy remained a highly significant predictor of progression-free survival even after controlling for bulky disease and International Prognostic Score more than 2.
  • CONCLUSION: These data indicate that PET status after chemotherapy is strongly predictive of FFP with the Stanford V regimen despite the use of consolidative radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Positron-Emission Tomography
  • [MeSH-minor] Adult. Bleomycin / therapeutic use. Disease Progression. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Mechlorethamine / therapeutic use. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / drug therapy. Neoplasm Staging. Predictive Value of Tests. Prednisone / therapeutic use. Recurrence. Retrospective Studies. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664458.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; Stanford V protocol
  •  go-up   go-down


11. Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group: Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):19-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
  • PURPOSE: The use of radiotherapy in patients with advanced Hodgkin's lymphoma (HL) is controversial.
  • The purpose of this study was to describe the role of radiotherapy in patients with advanced HL who were in partial remission (PR) after chemotherapy.
  • METHODS: In a prospective randomized trial, patients <70 years old with previously untreated Stage III-IV HL were treated with six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycine, vinblastine hybrid chemotherapy.
  • Patients in complete remission (CR) after chemotherapy were randomized between no further treatment and involved-field radiotherapy (IF-RT).
  • Those in PR after six cycles received IF-RT (30 Gy to originally involved nodal areas and 18-24 Gy to extranodal sites with or without a boost).
  • RESULTS: Of 739 enrolled patients, 57% were in CR and 33% in PR after chemotherapy.
  • Patients in PR had bulky mediastinal involvement significantly more often than did those in CR after chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Logistic Models. Male. Mechlorethamine / administration & dosage. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / radiotherapy. Middle Aged. Neoplasms, Second Primary / etiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Survival Rate. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone
  •  go-up   go-down


12. Zapatero A, López MA, Cerezo L, De Vidales CM, MarIn A, Pérez-Torrubia A: Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era. Hematology; 2002 Feb;7(1):43-50
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era.
  • PURPOSE: To analyse the long term outcome, pattern of failure and treatment related complications after radiation therapy (RT) with or without chemotherapy for stage I-III Hodgkin's disease (HD).
  • MATERIAL AND METHODS: Detailed records from 86 patients with stage I-III HD treated between 1989 and 1998, were retrospectively reviewed.
  • Seventeen patients with favourable stage I-IIA were treated with RT alone, and the remaining 69 patients with combined modality treatment (CMT).
  • Patients treated with RT received extended-field or subtotal nodal irradiation (STNI) to a total dose of 36-54 Gy, and patients with CMT, received involved-field irradiation to a lower doses, 26-40 Gy.
  • The median follow-up time was 50 months (range 16-180).
  • RESULTS: The 10-year overall survival (OS) for the whole group was 96% (SE 2%), 100% for stage I, 95% for stage II and 100% for stage III patients.
  • Of potential prognostic factors analysed for statistical significance, only the response to chemotherapy (p=0.0393) was found to influence significantly OS rates.
  • Salvage treatment was effective in 10 of the 12 relapsed patients.
  • The 10-year freedom from treatment failure (FFTF) was 79% (SE 6%).
  • Although 8 (9.6%) of the 83 surviving patients developed late effects that could represent toxicity from the treatment, no patient died of late complications.
  • CONCLUSIONS: RT alone for favourable early stage HD attains good survival rates with a modest treatment related morbidity.
  • For patients with unfavourable stage II and stage III HD, CMT with limited RT provides a good to excellent prognosis.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171776.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V: Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol; 2000 Sep;11(9):1105-14
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
  • BACKGROUND: Evidence is recently accumulating that the novel BEACOPP (bleomycin (B), etoposide (E), adriamycin (A), cyclophosphamide (C), vincristine (O), procarbazine (P), prednisone (P)) chemotherapy is a highly effective treatment for advanced stage Hodgkin's disease.
  • Two dose variants of BEACOPP are currently tested in a phase III randomized multicenter trial of the GHSG.
  • To enable more extensive testing of BEACOPP we characterized its practicability regarding schedule adherence, acute hematotoxicity and need for supportive treatment.
  • PATIENTS AND METHODS: Data of 858 patients (6592 therapy cycles) from 184 participating institutions were evaluated.
  • Planned total drug doses of the baseline variant (arm 1) were 80, 2400, 200, 5200, 11.2, 5600 and 4480 mg/m2 for B, E, A, C, O, P and P, respectively.
  • RESULTS: Median dose adherence (dose actually given relative to planned arm 1 dose) in arm 1 was 1.0 for all drugs.
  • Relative dose escalation of E, A, and C actually maintained in arm 2 was 1.83, 1.37 and 1.77 (medians), respectively, and 70% of patients maintained elevated dose levels throughout the entire treatment.
  • Time courses of leukocytes in arm 2 showed more severe but not more prolonged leukocytopenia compared with arm 1.
  • Despite increased hematotoxicity, moderate dose escalation is safe for the majority of the patients with G-CSF assistance and standard supportive treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11061603.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


14. Pectasides D, Economopoulos T, Kouvatseas G, Antoniou A, Zoumbos Z, Aravantinos G, Tsatalas C, Halikia A, Nikolaides C, Kiamouris C, Pappa E, Pavlidis N, Skarlos D, Fountzilas G, Dimopoulos MA: Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience. Oncology; 2000 May;58(4):286-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience.
  • Testicular non-Hodgkin's lymphoma is an uncommon disease and its outcome following chemotherapy and/or radiotherapy has been variable.
  • A retrospective analysis was performed on 26 patients with primary testicular lymphoma treated predominantly with anthracycline-based chemotherapy between 1984 and 1999.
  • There were 11 (42.3%) patients with high grade lymphoma, 12 (46.2%) with intermediate grade, 1 (3.8%) with low grade and 2 (7.7%) were not classified.
  • According to the Ann-Anbor staging system, 18 patients (69.2%) had early (stage I/II) and 8 (30.8%) advanced (stage III/IV) disease.
  • Chemotherapy was administered to 24 patients including 22 patients who received anthracycline-based chemotherapy.
  • Two stage IEA patients were treated with orchidectomy and adjuvant radiotherapy to the regional lymph nodes without systemic chemotherapy.
  • Chemotherapy alone resulted in a complete remission (CR) in 14 (58.3%) of 24 patients and partial remission in 1 (4.2%), amounting to an overall response rate (RR) of 62.5%.
  • Of the 5 stage I patients who had chemotherapy on an adjuvant basis, 4 (80%) had CR/no evidence of disease.
  • Of the 11 stage II patients, 8 (72.7%) achieved CR and 1 (9.1%) PR (overall RR of 81.8%).
  • CR was obtained in 2 (25%) of 8 stage III/IV patients.
  • Both patients remain disease free for 26 and 65 months.
  • Excluding the 5 stage I patients, chemotherapy resulted in a CR in 10/19 (52.6%) patients and a PR in 1/19 (5.2%), inducing an overall RR of 57.8%.
  • After a median follow-up of 87 months (range 0.13-145.5+ months) the median survival time was 31 months (range 0.13-145.5+ months) and the median time to progression (TTP) 17 months (range 0.13-145.5+ months).
  • The median TTP was significantly higher in early disease compared to that of advanced disease (52 vs. 3 months, p = 0.02).
  • Of the 3 patients who relapsed following disease-free status, CNS involvement occurred in 2 stage II patients and contralateral testis involvement in 1 stage IEA, respectively.
  • The latter remained disease free for 2 years following orchidectomy alone.
  • The other 2 patients who relapsed did not respond to salvage chemotherapy and died.
  • In conclusion, patients with primary testicular lymphoma have a poor outcome, despite the treatment with anthracycline-containing regimens.
  • Treatment with anthracycline-based chemotherapy is recommended in patients at early stages.
  • In advanced disease, more intensive or investigational regimens should be considered.
  • Because the relapse rate in the CNS and contralateral testis is quite high in most studies, prophylactic CNS treatment and radiotherapy to the other testis should be included in the management of testicular lymphoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10838493.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


15. Jost LM, Honegger HP, Stahel RA: [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich]. Schweiz Med Wochenschr; 2000 Jan 22;130(3):60-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
  • [Transliterated title] Hochdosis-Chemotherapie mit autologer Stammzelltransplantation: 11 Jahre Zürcher Erfahrung.
  • High-dose chemotherapy with autologous bone marrow or peripheral blood stem cell transplantation has gained widespread acceptance for the treatment of certain malignancies.
  • Since the introduction of this therapy in 1988 we have treated 272 patients.
  • Indications for high-dose chemotherapy were high-risk large cell lymphoma and lymphoblastic or Burkitt lymphoma in first remission (73 patients), non-Hodgkin's lymphoma in chemosensitive relapse (65 patients), Hodgkin's lymphoma in relapse (52 patients), germ cell tumours with inadequate response to chemotherapy (34 patients), multiple myeloma (29 patients), and other malignancies (19 patients).
  • Treatment mortality was 1.8%.
  • High-dose chemotherapy with autologous stem cell transplantation has become a safe procedure and is considered the treatment of choice for relapsed large cell lymphoma, relapsed Hodgkin's disease, stage II or III multiple myeloma, and germ cell tumours with inadequate response to cisplatin-based chemotherapy.
  • In other situations, including aggressive lymphoma with risk factors, acute leucaemia or breast cancer, the superiority of high-dose over conventional chemotherapy remains to be proven.
  • Patients with such diseases should not receive high-dose chemotherapy outside a controlled clinical study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Lymphoma / therapy. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Switzerland. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10683881.001).
  • [ISSN] 0036-7672
  • [Journal-full-title] Schweizerische medizinische Wochenschrift
  • [ISO-abbreviation] Schweiz Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


16. Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, Pastano R, Pruneri G, Mazzetta C, Ghielmini M, Cavalli F: ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. Br J Haematol; 2004 Jun;125(5):584-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
  • We retrospectively analysed toxicities and clinical results of 61 Hodgkin's lymphoma patients treated with chlorambucil, vinblastine, procarbazine, doxorubicin, bleomycin, vincristine and etoposide (ChlVPP/ABVVP), delivered in a weekly alternate schedule.
  • Of 61 patients, 33 were in stages III-IV, 21 in stage IIB and seven in stage IIA with bulky disease or extranodal presentation.
  • Involved field radiotherapy (IFRT) (30-35 Gy) was delivered to 31 patients with residual disease after chemotherapy or bulky disease at diagnosis.
  • Of 61 patients, 58 (95%) achieved complete clinical or radiological remission after chemotherapy and IFRT.
  • One patient developed secondary acute myeloid leukaemia 1 year after ChlVPP/ABVVP.
  • Due to the retrospective nature of this study, no definitive conclusions could be drawn about the clinical activity of ChlVPP/ABVVP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chlorambucil / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Neoplasms, Second Primary / therapy. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15147373.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin
  •  go-up   go-down


17. Al-Salman J, Salib H, Boonswang P: Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy. Med Oncol; 2001;18(4):277-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy.
  • The clinical course of follicular lymphoma (FL) is well known.
  • Although it is a chemosensitive disease, thereby allowing substantial palliation, recurrence is the rule; only a small subset who presents with limited stage disease is cured.
  • Multiple attempts have been made over the past two decades to improve the survival of patients with FL, and a large number of phase III trials have been reported.
  • These have included a variety of different therapeutic interventions, such as combination chemotherapy, recombinant interferons, new cytotoxic drugs, and immunologic agents.
  • Most studies have not demonstrated that the use of a particular therapy convincingly prolongs survival.
  • Follicular lymphoma cells express CD20 and are associated in most cases with the t(14:18) chromosomal translocation.
  • Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen, which has been utilized for the therapy of B-cell non-Hodgkin's lymphoma.
  • Rituximab was shown to be active in FL, and studies of its effectiveness in combination with cytotoxic chemotherapy to increase the response rate are forthcoming.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ileal Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Proto-Oncogene Proteins c-bcl-2. Rituximab. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1993 May;17(5):429-42 [8470758.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):655-61 [10442187.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):81-8 [10848785.001]
  • [Cites] Can J Gastroenterol. 1997 Jan-Feb;11(1):31-4 [9113795.001]
  • [Cites] Oncol Nurs Forum. 1998 May;25(4):669 [9599347.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Ann Surg. 1980 May;191(5):593-8 [6989331.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:23-7 [10707774.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Oncology (Williston Park). 2000 Mar;14(3):321-6, 329; discussion 330-2, 338 [10742961.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:123-6 [10707793.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):2-11 [10561012.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):349-54 [1721524.001]
  • (PMID = 11918454.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Proto-Oncogene Proteins c-bcl-2; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol; 2000 May;18(10):2010-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
  • PURPOSE: S8809 is a randomized phase III trial determining whether intensive cytoreductive treatment, followed by interferon consolidation at the time of minimal residual disease, prolongs the progression-free survival (PFS) or overall survival (OS) of indolent lymphoma patients.
  • PATIENTS AND METHODS: Five hundred seventy-one patients with previously untreated stage III or IV low-grade non-Hodgkin's lymphoma were registered.
  • Patients received six to eight cycles of prednisone, methotrexate, doxorubicin, cyclophosphamide, and etoposide/mechlorethamine, vincristine, procarbazine, and prednisone (ProMACE[day 1]-MOPP[day 8]) chemotherapy or chemotherapy plus radiotherapy.
  • Interferon alpha-2b 2 mU/m(2) was given subcutaneously three times weekly for 2 years.
  • With a median follow-up time from randomization among patients still alive of 6.2 years, the median PFS time was 4.1 years for patients who received interferon consolidation therapy and 3.2 years for patients who were observed after ProMACE-MOPP induction (P =.25).
  • CONCLUSION: Interferon alpha consolidation therapy after intensive treatment with anthracycline-containing combination chemotherapy and involved-field radiation therapy does not prolong the PFS or OS of patients with low-grade non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon-alpha / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease Progression. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Methotrexate / adverse effects. Methotrexate / therapeutic use. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Radiotherapy, Adjuvant. Recombinant Proteins. Remission Induction. Vincristine / adverse effects. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2000 Sep 15;18(18):3322 [10986069.001]
  • [CommentIn] J Clin Oncol. 2000 May;18(10):2007-9 [10811663.001]
  • (PMID = 10811664.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA46282; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 35S93Y190K / Procarbazine; 43K1W2T1M6 / interferon alfa-2b; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol
  •  go-up   go-down


19. Sun XF, Liu DG, Zhen ZJ, Chen XQ, Xia Y, Wang ZH, He YJ, Guan ZG: [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):581-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma].
  • OBJECTIVES: To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas (B-NHL).
  • Of them 18 cases were Burkitt's lymphoma, 16 diffuse large B cell lymphoma and 8 anaplastic lymphoma.
  • There were 10 cases in stage II and 32 in stage III/IV.
  • Of the 5 PR patients, I received autologous hematopoietic stem cell transplantation, 3 received radiotherapy for residual disease and 1 just under watching.
  • 24%, being 100% for stage II and 80.95% for stage III/IV.
  • CONCLUSION: Short term and intensive chemotherapy can improves the efficacy and survival rate of childhood and adolescent B-NHL, especially for advanced stage patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Feasibility Studies. Female. Follow-Up Studies. Humans. Infant. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532964.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB, Oncology Practice Pattern Study Working Group: The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma; 2001 Jun;2(1):47-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
  • The purpose of this historical case series study was to evaluate the association of age on delivered dose intensity of initial CHOP (cyclophosphamide/doxorubicin/ vincristine/prednisone) chemotherapy and the occurrence of hospitalizations for febrile neutropenia for patients with intermediate-grade non-Hodgkin's lymphoma (NHL).
  • We reported on 577 of the study patients (62%) who received initial CHOP chemotherapy.
  • In patients with advanced-stage NHL (stage III/IV), older patients received fewer cycles of CHOP (< 6 cycles, 35% vs. 22%; P < 0.05) than younger patients.
  • Older patients were planned for lower average relative dose intensity (ARDI < or = 80%; P < 0.05) and had more heart disease and comorbid conditions (P < 0.05) than younger patients.
  • Multiple logistic regression models showed that older patients were more likely to receive a lower dose intensity (ARDI < or = 80%; odds ratio = 2.46, 95% confidence interval [CI]: 1.62-3.72) during their first 3 cycles of therapy and to experience more hospitalizations for febrile neutropenia (odds ratio = 2.17, 95% CI: 1.43-3.30).
  • We found the dose intensity of delivered CHOP chemotherapy for elderly patients to be less than standard CHOP therapy and the risk of hospitalizations for febrile neutropenia to be greater than in younger patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fever / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / chemically induced
  • [MeSH-minor] Adult. Age Factors. Aged. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hospitalization. Humans. Male. Middle Aged. Odds Ratio. Prednisone / administration & dosage. Retrospective Studies. Risk Factors. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Fever.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707870.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Brenot-Rossi I, Bouabdallah R, Di Stefano D, Bardou VJ, Stoppa AM, Camerlo J, Sauvan R, Gastaut JA, Pasquier J: Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med; 2001 Oct;28(10):1482-8
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy.
  • Evaluation of the response to therapy is important for optimal selection of treatment strategy in patients with Hodgkin's disease (HD).
  • Refractory disease requires intensive high-dose chemotherapy, whereas unnecessary treatment should be avoided in patients in complete remission.
  • The purpose of this study was to evaluate the contribution of gallium-67 scintigraphy in predicting the clinical outcome in patients with HD and mediastinal involvement on the basis of scan results at the end of chemotherapy.
  • Seventy-four patients with HD and mediastinal involvement were retrospectively investigated with 67Ga scintigraphy 72 h after injection of 220 MBq 67Ga citrate (planar and single-photon emission tomographic studies) following the completion of chemotherapy.
  • At the same time, they all underwent computed tomography (CT).
  • The disease status was newly diagnosed disease in 64 of the patients and relapse in 10.
  • Forty-one patients had stage I or II disease and 33 patients had stage III or IV disease.
  • Twenty-two patients had bulky disease on initial diagnosis.
  • At the end of chemotherapy, all 74 patients showed regression of the mass by more than 50% (50%-100%) on CT.
  • Patients were divided into two groups according to the positivity or negativity of the gallium scan after chemotherapy: 61 patients had negative and 13 patients had positive gallium scans.
  • In the gallium-positive group, 84.6% of the patients had recurrent disease and 61.5% were alive after intensive chemotherapy.
  • Disease-free survival differed significantly between patients with positive and patients with negative gallium scans at the end of chemotherapy (P<0.0001).
  • It is concluded that even if gallium scan is performed at the end of chemotherapy, it can predict outcome.
  • Alternative therapy may be required on the basis of gallium scan results obtained after treatment.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / mortality. Hodgkin Disease / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685490.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


22. Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M: Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol; 2000 Mar;30(3):146-52
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
  • BACKGROUND: The main form of cytotoxic treatment for advanced Hodgkin's disease (HD) is conventional dose multiagents chemotherapy.
  • As HD is not common in Japan, we conducted a phase II study of the commonly used combination chemotherapy (CCT) regimen established in the West for Japanese patients with advanced HD to confirm the efficacy and safety.
  • METHOD: Between October 1989 and February 1993, a multicenter phase II study of alternating CCT C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, vinblastine, bleomycin, dacarbazine) to evaluate its clinical usefulness for clinical stage (cS) II-IV HD was conducted by the Lymphoma Study Group of the Japan Clinical Oncology Group.
  • For 40 cS II and 27 cS III/IV patients the response rate was 95.0% with 90.0% CR and 88.9% with 74.1% CR, respectively.
  • Those of cS II and cS III/IV were 92.5 and 73.1%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.1025).
  • Those of cS II and cS III/IV were 77.5 and 65.7%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.2483).
  • There was GPT elevation in 4.5%, nausea/vomiting in 11.9% and CNS in 1.5% of patients, but there was no treatment-related death.
  • CONCLUSION: The C-MOPP/ABVd regimen for Japanese patients with advanced HD is considered to be one of the effective CCTs according to the results of the present phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prednisolone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10798542.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ABVD protocol; CMOPP protocol
  •  go-up   go-down


23. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The radiation dose was 39.9-40.5 Gy in 30 fractions.
  • The median treatment time was 22 days with twice-daily involved-field RT.
  • Recurrence or progression outside the RT volume was regarded as distant disease.
  • The initial diagnosis was Stage I-II in 56% and Stage III-IV in 44%.
  • The disease bulk was > or =10 cm in 35% (n = 12).
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • The initial treatment was chemotherapy in 32 patients (94%); 71% were refractory to initial chemotherapy and 29% developed a relapse after an initial response.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose Fractionation. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mahé Ma, Bourdin S, Le Pourhiet-Le Mevel A, Moreau P, Campion L, Hamidou M, Milpied N, Moreau A, Gaillard F, Harousseau JL, Cuillière JC: Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy. Int J Radiat Oncol Biol Phys; 2000 Jun 1;47(3):735-8
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy.
  • PURPOSE: To evaluate the efficacy of total abdominopelvic (TAI) and total body irradiation (TBI) in heavily pretreated follicular non-Hodgkin's lymphoma (NHL).
  • All had Stage III or IV, Class B, C, D NHL in the working formulation and failed after receiving 1-5 regimens of chemotherapy.
  • TAI was given at 20 Gy over a 3-week period.
  • TBI was delivered in two successive half-body irradiations of 15 Gy over a 2-week period with a 4-week interval between each.
  • Median survival was 62 months, 5-year and 10-year overall survival was 59% and 41%, and disease-free survival was 56% and 30%, respectively.
  • Grade III or IV toxicity was gastrointestinal in 38% of patients and hematologic in 30%.
  • CONCLUSION: Extended-field irradiation is feasible and efficient after failure of chemotherapy in follicular NHL.
  • [MeSH-major] Lymphoma, Follicular / radiotherapy. Whole-Body Irradiation
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Salvage Therapy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10837958.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. Eich HT, Gossmann A, Engert A, Kriz J, Bredenfeld H, Hansemann K, Skripnitchenko R, Brillant C, Pfistner B, Staar S, Diehl V, Müller RP, German Hodgkin Study Group: A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys; 2007 Nov 15;69(4):1187-92
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
  • PURPOSE: The role of radiotherapy (RT) after intensive chemotherapy in patients with advanced stage Hodgkin's lymphoma (HL) is still unclear.
  • The German Hodgkin Study Group (GHSG) randomized HD12 trial was designed to test whether consolidative RT in the region of initial bulky disease and of residual disease is necessary after effective chemotherapy.
  • METHODS AND MATERIALS: A total of 1661 patients aged 16 to 65 years with HL in Stage IIB (large mediastinal mass and/or E-lesions) or Stage III to IV were randomized from January 1999 to January 2003 according to a factorial design between: 8 esc.BEACOPP + RT (arm A), 8 esc.BEACOPP non-RT (arm B), 4+4BEACOPP + RT (arm C), 4+4BEACOPP non-RT (arm D).
  • After a median observation time of 48 months the FFTF rate was 86% and the OS 92%.
  • The panel defined initial bulky disease in 800 patients and residual disease in 600 patients.
  • The panel recommended continuation of therapy according to the randomization for 934 of 1084 patients and additive RT independently from the randomization arm for 145 of 1084 patients.
  • CONCLUSIONS: The study showed that RT can be reduced substantially after effective chemotherapy.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Middle Aged. Neoplasm, Residual. Prednisone / administration & dosage. Procarbazine / administration & dosage. Quality Assurance, Health Care. Radiotherapy / standards. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17703895.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


26. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI, Southwest Oncology Group: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol; 2006 Sep 1;24(25):4143-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
  • PURPOSE: Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial.
  • This study was performed to determine the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab.
  • PATIENTS AND METHODS: From 1999 to 2000, the Southwest Oncology Group (SWOG) conducted a phase II trial (S9911) to test a novel new regimen consisting of six cycles of CHOP chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I-131 tositumomab in 90 eligible patients with previously untreated, advanced-stage FL.
  • After a median follow-up time of 5.1 years, the estimated 5-year overall survival (OS) rate was 87%, and the progression-free survival (PFS) rate was 67%.
  • An analysis according to the Follicular Lymphoma International Prognostic Index showed that 21% of patients had high-risk features, 44% had intermediate-risk features, and 34% had low-risk features.
  • ) CONCLUSION: A prospective, phase III, randomized Intergroup Trial is currently underway comparing the efficacy of the promising CHOP + tositumomab/iodine I-131 tositumomab regimen with the efficacy of CHOP + rituximab.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prednisone / administration & dosage. Radioimmunotherapy / methods. Survival Analysis. Treatment Outcome. United States. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):915-6; author reply 916-7 [17327620.001]
  • (PMID = 16896003.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58348; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / iodine-131 anti-B1 antibody; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. Girshovich MM, Kanaev SV, Pozharisskiĭ KM, Golovanov SG, Barbashov AI: [New prognostic factors in the treatment of patients with stage-III Hodgkin's disease]. Vopr Onkol; 2010;56(4):424-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New prognostic factors in the treatment of patients with stage-III Hodgkin's disease].
  • Our data are presented on evaluation of chemoradiotherapy of 365 patients with stage III Hodgkin's disease.
  • Patients with stage IIIA tumors revealed the following significant differences of overall and relapse-free survival (p < or = 0.00001): 15-year overall survival (nodular sclerosis G1) - 95% vs.G2 - 45%; 15-year relapse-free survival: G1 - 86%, G2 - 32%.
  • In stage IIIB group, overall survival (50%) was significantly lower as compared with 70%.
  • Involvement foci significantly regressed by less than 75% (p = 0.044) after 2-4 cycles of preliminary combination chemotherapy.
  • Our results suggest that differentiated criteria be used for prognosis of stage III Hodgkin's disease treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. Risk Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20968021.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


28. Kanaev SV, Golovanov SG, Girshovich MM, Gershanovich ML: [Clinical evaluation of combined treatment of stage III(B) Hodgkin's disease]. Vopr Onkol; 2006;52(5):525-30
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of combined treatment of stage III(B) Hodgkin's disease].
  • Patients with stage III Hodgkin's disease (110) received 2-3 courses of combination chemotherapy followed by total or subtotal irradiation, or exposure of primarily involved lymph nodes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168360.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


29. Kanaev SV, Girshovich MM, Golovanov SG, Gershanovich ML: [Is irradiation of intact ileoinguinal lymph nodes necessary in radiochemotherapy for stage-III Hodgkin's disease?]. Vopr Onkol; 2007;53(4):453-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is irradiation of intact ileoinguinal lymph nodes necessary in radiochemotherapy for stage-III Hodgkin's disease?].
  • Data are presented on radiochemotherapy (1-4 cycles of combined therapy+total (TI) or subtotal (STI) irradiation of lymph nodes) given to 120 patients, with stage III Hodgkin's disease, whose ileoinguinal lymph nodes were intact.
  • Analysis of overall survival of patients with stage III Hodgkin's disease showed that 87% of STI patients survived for 10-years as compared with 73% in TI (p=0.07).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymph Nodes / radiation effects
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Groin. Humans. Ileum. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969410.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


30. Bertz H, Zeiser R, Lange W, Fetscher S, Waller CF, Finke J: Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol; 2004 Sep;15(9):1419-24
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
  • BACKGROUND: To evaluate the long-term benefit from high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT), as part of the initial treatment for patients with chemosensitive, high-grade B non-Hodgkin's lymphoma (hg B-NHL), stratified according to the age-adjusted International Prognostic Index (aaIPI).
  • PATIENTS AND METHODS: Eligible patients were 33 consecutive hg B-NHL patients responding to first-line chemotherapy and fulfilling at least one of the following criteria: stage III or IV, bulky disease, elevated lactate dehydrogenase or failure to achieve complete remission (CR).
  • All patients received HDCT with ASCT after a minimum of 6 weeks of VACOP-B standard therapy and VIP-E for mobilization.
  • No treatment-related death occurred.
  • Twenty-five of 33 patients are in sustained CR with a disease-free survival of 76% [95% confidence interval (CI) 67% to 86%].
  • CONCLUSIONS: The results suggest that up-front HDCT with ASCT may improve long-term outcome in high-risk patients with chemotherapy-sensitive hg B-NHL when compared to historic populations treated solely with dose-intense chemotherapy.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15319249.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


31. Ott OJ, Rödel C, Gramatzki M, Niedobitek G, Sauer R, Grabenbauer GG: Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma. Strahlenther Onkol; 2003 Oct;179(10):694-701

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma.
  • BACKGROUND: To evaluate retrospectively long-term results and patterns of recurrence in patients with low-grade non-Hodgkin's lymphoma (NHL) Ann Arbor stage I-II and limited stage III.
  • 48 patients (83%) presented with follicular lymphoma (stage I: 23 patients, stage II and III: 15 and ten patients, respectively).
  • Irradiation was applied with a median total dose of 40 Gy.
  • 13 patients (22%) additionally received chemotherapy.
  • End points of the investigation were remission rate, overall- and disease-free survival, and patterns of recurrence, as well as the prognostic impact of age, B-symptoms, chemotherapy, irradiation dose, treatment volume, and Ann Arbor stage.
  • RESULTS: 6 weeks after treatment 91% of the patients had complete, 7% partial response.
  • One patient (2%) was classified as progressive disease.
  • Corresponding disease-free survival rates were 73% and 63%.
  • In the subgroup of patients with follicular lymphoma 92% were found in complete, 6% in partial remission, one patient (2%) with progressive disease.
  • Overall survival rates at 5 und 10 years were 87% and 70%, disease-free survival rates 75% and 64%, respectively.
  • CONCLUSIONS: Our results maintain external radiotherapy as a curative concept in the treatment of limited stage low-grade lymphoma, especially in younger patients.
  • [MeSH-major] Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Nodes / radiation effects. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Prognosis. Radiotherapy Dosage. Regression Analysis. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14566478.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I: [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. Harefuah; 2000 Sep;139(5-6):174-9, 248, 247
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
  • High dose chemotherapy and autologous stem cell transplantation are widely used in relapsed and primary refractory Hodgkin's disease.
  • We transplanted 42 patients with Hodgkin's disease between 1990-1998.
  • 29 (69%) were transplanted after relapse and 13 (31%) were refractory to first line therapy.
  • At initial diagnosis: 57% had stage III-IV disease and B symptoms were present in 52%.
  • Prior to transplantation, 45% of the relapsed group were in the advanced stage.
  • 2 (5%) died from transplant-related complications and MDS/AML developed in 2 (5%) after transplantation.
  • The 3-year overall survival (OS) and disease-free survival (DFS) were 68% and 60%, respectively.
  • No prognostic factors for outcome of transplantation were found, most probably due to the limited number of patients and the high variability of disease characteristics.
  • We conclude that high dose chemotherapy and autologous stem cell transplantation are effective and relatively safe for relapsed or primary refractory Hodgkin's disease.
  • The DFS at 3 years was longer for those transplanted after relapse than those with primary refractory disease, but not significantly.
  • Patients with primary refractory disease can be salvaged with high dose chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Carmustine / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Mechlorethamine / administration & dosage. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Retrospective Studies. Survival Rate. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11062945.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] ISRAEL
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; ABVD protocol; BEAM protocol; MOPP protocol
  •  go-up   go-down


33. Kanaev SV, Gershanovich ML, Pozharisskiĭ KM, Girshovich MM, Malinin AP, Golovanov SG: [Clinical evaluation of efficacy of chemoradiotherapy for Hodgkin's disease]. Vopr Onkol; 2004;50(6):652-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of efficacy of chemoradiotherapy for Hodgkin's disease].
  • [Transliterated title] Klinicheskaia otsenka éffektivnosti khimioluchevogo lecheniia limfomy Khodzhkina III (A,B) stadii.
  • Patients with stage III (A,B) Hodgkin's disease (366) received chemoradiotherapy consisting of 2-4 courses of combined modality treatment followed by total or subtotal irradiation of lymph nodes.
  • Overall 10-year (84%) and 15-year (79%) and relapse-free 10-year (85%) and 15-year (82%) survival was reported in stage IIIA cases.
  • If, following combined modality therapy, intoxication symptoms were aborted in stage IIIB patients; fairly good results were obtained after total and subtotal irradiation of lymph nodes or involved areas (10-year (70%) and 15-year (65%) overall and 10-year (75%) and 15-year (75%) relapse-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755057.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


34. Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI: Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol; 2001 Nov 15;19(22):4238-44
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
  • PURPOSE: The management of early-stage Hodgkin's disease in the United States is controversial.
  • To evaluate whether staging laparotomy could be safely avoided in early-stage Hodgkin's disease and whether chemotherapy should be a part of the treatment of nonlaparotomy staged patients, a phase III intergroup trial was performed.
  • PATIENTS AND METHODS: Three hundred forty-eight patients with clinical stage IA to IIA supradiaphragmatic Hodgkin's disease were randomized without staging laparotomy to treatment with either subtotal lymphoid irradiation (STLI) or combined-modality therapy (CMT) consisting of three cycles of doxorubicin and vinblastine followed by STLI.
  • Treatment was well tolerated, with only one death on each arm attributed to treatment.
  • CONCLUSION: These results demonstrate that it is possible to obtain a high FFS rate in a large group of stage IA to IIA patients without performing staging laparotomy and that three cycles of chemotherapy plus STLI provide a superior FFS compared with STLI alone.
  • Extended follow-up is necessary to assess freedom from second relapse, overall survival, late toxicities, patterns of treatment failure, and quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymphoid Tissue / radiation effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11709567.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA04920; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35262; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA52386; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58348; United States / NCI NIH HHS / CA / CA58415; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA96429
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin
  •  go-up   go-down


35. Sotnikov VM, Pan'shin GA, Datsenko PV, Ivashin AV, Smol'tsova NN: [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):443-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma].
  • Immediate and end results of chemoradiotherapy of 225 patients (average age--43 years) with primary aggressive non-Hodgkin's lymphomas stage III-IV were evaluated.
  • Stage 1 of treatment included 4-8 cycles of chemotherapy (ACOP and other standard protocols); stage 2--irradiation of residual foci with 20-50 Gy, or 20-36 Gy for originally extensive and extralymphatic foci when in full remission.
  • The disease is specific, so relapse-free survival in cases of generalized primary aggressive lymphoma in full remission remained unchanged too whatever the stage at which full remission emerged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947367.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


36. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH: Predicting chemotherapy response and comparing with P-glycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas. Cancer Lett; 2001 Sep 20;170(2):139-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting chemotherapy response and comparing with P-glycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas.
  • The purposes of this study were to predict the chemotherapy response of untreated malignant lymphomas (ML) using a technetium-99m tetrofosmin (Tc-TF) scan and to compare Tc-TF results with P-glycoprotein (Pgp) expression.
  • Before undergoing chemotherapy, 25 patients with ML were enrolled in this study.
  • The chemotherapy response was evaluated in the first 1-2 years after the completion of treatment.
  • No significant differences in the incidences of good and poor responses were found between Hodgkin's disease patients and non-Hodgkin's lymphoma patients, stage I-II patients and III-IV patients, patients aged >40 and patients aged < or =40 years, and patients with and without B symptoms.
  • Compared with other prognostic factors, Tc-TF scan results and Pgp expression more accurately predict the chemotherapy response in patients with ML.
  • [MeSH-major] Lymphoma / metabolism. Organophosphorus Compounds. Organotechnetium Compounds. P-Glycoprotein / biosynthesis. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11463491.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


37. Epelbaum R, Haim N, Ben-Shahar M, Valtuch I, Faraggi D, Sharabi-Nov A, Ben-Arie Y, Cohen Y: [The chemotherapeutic treatment of advanced Hodgkin's disease]. Harefuah; 2001 Apr;140(4):311-5, 367
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The chemotherapeutic treatment of advanced Hodgkin's disease].
  • Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A).
  • Radiation therapy was given to 1/3 of them.
  • The median age was 35 years, 58% had stage III and 42% had stage IV disease.
  • Multivariate analysis found age (above or below 65 years) and combination chemotherapy (with or without adriamycin) to be significant prognostic factors.
  • Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Multivariate Analysis. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Rate. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11303395.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


38. Proctor SJ, Mackie M, Dawson A, White J, Prescott RJ, Lucraft HL, Angus B, Jackson GH, Lennard AL, Hepplestone A, Taylor PR: A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer; 2002 Apr;38(6):795-806
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III).
  • The aim of the study was to identify all patients with poor risk Hodgkin's disease (HD) using a numerical prognostic index in a defined population and to recruit them into a trial of intensive chemotherapy prednisolone, vinblastine, doxorubicin, chlorambucil, etoposide, bleomycin, vincristine, procarbazine (PVACE-BOP)x3+autotransplant (Arm A) versus PVACE-BOPx5 (Arm B) in first remission.
  • In 10 years, the Scotland and Newcastle Lymphoma Group (SNLG) registered 930 patients with HD of whom 178 (19%) were identified as 'poor risk' by the SNLG index and were aged 16-59 years.
  • Of the 120 confirmed poor risk HD cases, all completed PVACE-BOPx3 with a 93% Complete Response/unconfirmed Complete Response (CR/CRu) rate.
  • With a median follow-up of 6 years, both arms of the trial have a similar time to treatment failure (TTF) (Arm A 79%+/-11 versus 85%+/-7 Arm B, P=0.35).
  • Advanced stage 'good risk' patients not included in the trial receiving standard therapy with CLVPP or ABVD had a 75% 5-year survival.
  • The study demonstrates that PVACE-BOP therapy in the poorest risk group (58% had an IPI>/=3) produces excellent CR rates (93%) and overall survival with minimal toxicity, and that the substitution of autotransplant in first CR does not improve outcome.
  • The placing of a randomised control trial within the context of a population-based study of HD enhances the validity of the outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation / methods. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy / methods. Female. Follow-Up Studies. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Recurrence. Risk Factors. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11937314.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, Todisco E, Bramanti S, Mazza R, Russo F, Timofeeva I, Santoro A: Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Hematol; 2007 Feb;82(2):122-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
  • We designed a prospective study to evaluate the feasibility and efficacy of tandem high-dose chemotherapy (HDCT) in the treatment of refractory or relapsed Hodgkin's lymphoma (HL).
  • Thirty-two patients were treated with salvage chemotherapy (IGEV, ifosfamide, gemcitabine, and vinorelbine) and chemo-sensitive patients received a first HDCT course with melphalan 200 mg/m(2) (MEL200) and a second BEAM course.
  • The median time interval between the two HDCT courses was 66 days.
  • No grade III or IV renal, hepatic, lung, cardiac, and neurological toxicity was observed.
  • Severe (grade III and IV) oral mucositis was the most prominent complication affecting 60 and 50% of patients after MEL200 and BEAM, respectively.
  • In an intention-to-treat analysis, the overall response rate increased after each stage of protocol, ranging from 47% to 65% and 75% after IGEV, MEL200, and BEAM, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Cytarabine / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Prospective Studies. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17019686.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; Q6C979R91Y / vinorelbine; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; BEAM protocol
  •  go-up   go-down


40. Biasoli I, Franchi-Rezgui P, Sibon D, Brière J, de Kerviler E, Thieblemont C, Levy V, Gisselbrecht C, Brice P: Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. Ann Oncol; 2008 Nov;19(11):1915-20
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy.
  • BACKGROUND: Data on factors influencing inclusion of Hodgkin's lymphoma (HL) patients in randomized clinical trials (RCT) are limited and, for the present study they were analyzed in a RCT for III/IV HL.
  • PATIENTS AND METHODS: All patients with stage III/IV HL referred to the Saint-Louis Hospital between January 2003 and May 2007 were studied.
  • A Groupe d'Etudes des Lymphomes de l'Adulte/European Organisation for Research and Treatment of Cancer RCT, to compare ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with increased-dose BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), was open for recruitment.
  • Seven patients were ineligible, 22 refused to participate, and 21 were not enrolled due to the physician's decision.
  • Main reasons for patients' refusal were standard treatment preference and concerns about experimental arm toxicity, mainly infertility risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552359.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


41. Kanaev SV, Gershanovich ML, Pozharisskiĭ KM, Girshovich MM, Golovanov SG: [Relevance of certain factors in the effectiveness of chemoradiotherapy for Hodgkin's disease]. Vopr Onkol; 2005;51(1):56-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relevance of certain factors in the effectiveness of chemoradiotherapy for Hodgkin's disease].
  • The relevance of certain factors in therapy of Hodgkin's disease was evaluated in patients with stage III A (232) and III B (97).
  • Among them were age above 45 years, an increase of more than 50% in blood-serum alkaline phosphatase, presence of at least five lesions, lymph node clusters of 5 cm in diameter and more, and male sex, when two introductory courses of combination chemotherapy were used in stage III A or 2-4 courses (stage III B), followed by total or subtotal irradiation of lymph nodes.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909808.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


42. Ng AK, Li S, Neuberg D, Silver B, Weeks J, Mauch P: Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians. Ann Oncol; 2004 Feb;15(2):261-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians.
  • BACKGROUND: The aim of this study was to explore variation in practice patterns and identify factors associated with physicians' treatment decisions for early-stage Hodgkin's disease.
  • METHODS: We conducted a one-time mail survey of oncologists randomly selected from directories of national oncology societies (n = 207) and Hodgkin's disease experts (n = 147).
  • The survey included questions on (i) physician factors, (ii) preferred treatment choices for six case scenarios of early-stage Hodgkin's disease that varied by patient factors, and (iii) thresholds for changing treatment recommendations.
  • For non-bulky Hodgkin's disease, 69% of respondents chose combined modality therapy (CMT).
  • On multivariate analysis, physician factors that independently predicted for choice of CMT included a high Hodgkin's disease case load (P = 0.02) and a high percentage of patients enrolled in clinical trials (P = 0.05).
  • Radiation oncologists had a lower threshold for adding radiation therapy (P = 0.02).
  • More experience with second malignancy cases and longer time in practice were associated with a higher threshold for adding radiation therapy (P = 0.04 and P = 0.008, respectively).
  • In stratified analyses, treatment decisions of non-experts were significantly influenced by physician factors, but not by patient factors.
  • Conversely, choices of Hodgkin's disease experts were insensitive to all physician factors, but experts were significantly more likely to select chemotherapy alone in young women and CMT in older patients.
  • CONCLUSIONS: Our results indicate that physician factors including practice type and experience may in part explain variation in practice pattern for Hodgkin's disease therapy.
  • Hodgkin's disease experts are more likely to tailor therapy according to individual patient factors.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14760120.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, Rombos J, Boussiotis VA, Vaiopoulos G, Kittas C, Pangalis GA: Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol; 2001 Nov-Dec;67(5-6):279-88
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites.
  • BACKGROUND: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60--70% of patients.
  • The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure-free survival (FFS) to be eligible for investigational treatment is necessary.
  • METHODS: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline-based regimens.
  • AAS was I in 4% of patients, II in 29%, III in 38% and IV in 29%.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11872075.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


44. Markova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plütschow A, Eich HT, Dietlein M, Engert A, Kozak T: FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol; 2009 Jul;20(7):1270-4
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
  • BACKGROUND: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) in patients with advanced-stage HL.
  • PATIENTS AND METHODS: From January 2004 to March 2007, 50 patients with newly diagnosed HL in clinical stages IIB with large mediastinal mass or extranodal disease, III and IV were treated according to the HD15 protocol of the German Hodgkin Study Group.
  • At a median observation time of 25 months, 2 of the 14 patients with a positive PET-4 had progressed or relapsed, while there was no progression or relapse in PET-4-negative patients.
  • CONCLUSION: Our results indicate a very good negative predictive value of PET-4 in advanced-stage HL patients treated with BEACOPP.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228806.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


45. Yu H, Hong XN, Li J, Peng LP, Ye L: [Prognostic factors of invasive non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 Jun;29(6):461-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of invasive non-Hodgkin's lymphoma].
  • OBJECTIVE: There is heterogeneity in non-Hodgkin's lymphoma.
  • The purpose of this study is to investigate the prognostic factors of invasive non-Hodgkin's lymphoma.
  • METHODS: From June 2002 to June 2006, 137 patients with invasive non-Hodgkin's lymphoma were treated by regular regimen consisting of radiotherapy and chemotherapy.
  • RESULTS: After treated with chemotherapy and radiotherapy, 35 (25.5%) patients achieved CR, 67 (48.9%) PR, 6 (4.3%) SD, 29 (21.2%) PD, ORR (objective response rate) of this series was 74.5%.
  • Multivariate analysis using Cox model indicated that clinical stage III-IV, PS score > or = 2, more than 2 external nodal involvement were closely correlated with overall survival.
  • CONCLUSION: The overall survival of invasive non-Hodgkin's lymphoma treated with present combined therapy regimen has been improved greatly.
  • However, further investigation is still needed for exploring more effective individualized treatment regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / statistics & numerical data. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974284.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down


46. Cairo MS, Krailo MD, Morse M, Hutchinson RJ, Harris RE, Kjeldsberg CR, Kadin ME, Radel E, Steinherz LJ, Morris E, Finlay JL, Meadows AT: Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia; 2002 Apr;16(4):594-600
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report.
  • Despite prolonged therapy (18 months), children with advanced non-lymphoblastic, non-Hodgkin's lymphoma (NHL) treated on previous Children's Cancer Group (CCG) trials achieved less than a 60% 5-year event-free survival (EFS).
  • In this study we piloted a shorter but more intensive protocol ('Orange') to determine the feasibility, safety, and efficacy of this alternative treatment approach.
  • Patients were stratified to standard-risk (5 months) vs high-risk (7 months) treatment.
  • High risk was defined as either bone marrow disease, CNS disease, mediastinal mass > or = one-third thoracic diameter at T5 and/or LDH > or =2 times institutional upper limits of normal.
  • This CCG hybrid regimen, 'Orange', of short and more intensive therapy resulted in a significant improvement in outcomes compared with the previous CCG trial of more prolonged but less intense therapy.
  • This regimen that deletes high-dose methotrexate, if confirmed in a larger trial, could be considered as an alternative treatment approach in children without high tumor burdens (LDH <2 x NL) and Murphy stage III disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / metabolism. Male. Methotrexate / administration & dosage. Neoplasm Staging. Pilot Projects. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11960338.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA02649; United States / NCI NIH HHS / CA / CA02971; United States / NCI NIH HHS / CA / CA03526; United States / NCI NIH HHS / CA / CA03750; United States / NCI NIH HHS / CA / CA03888; United States / NCI NIH HHS / CA / CA05436; United States / NCI NIH HHS / CA / CA07306; United States / NCI NIH HHS / CA / CA10198; United States / NCI NIH HHS / CA / CA10382; United States / NCI NIH HHS / CA / CA11796; United States / NCI NIH HHS / CA / CA13809; United States / NCI NIH HHS / CA / CA14560; United States / NCI NIH HHS / CA / CA17829; United States / NCI NIH HHS / CA / CA20320; United States / NCI NIH HHS / CA / CA26126; United States / NCI NIH HHS / CA / CA26270; United States / NCI NIH HHS / CA / CA27678; United States / NCI NIH HHS / CA / CA28882; United States / NCI NIH HHS / CA / CA29013; United States / NCI NIH HHS / CA / CA29314; United States / NCI NIH HHS / CA / CA42764
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


47. Stokoe CT, Ogden J, Jain VK: Activity of infusional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease. Oncologist; 2001;6(5):428-34
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of infusional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease.
  • INTRODUCTION: A phase II study of EPOCH chemotherapy in relapsed Hodgkin's disease was performed in 14 patients in a multicenter community setting.
  • Eleven out of 14 patients had advanced (stage III or IV) disease, but all patients had good performance status.
  • All 14 patients had received prior chemotherapy with ABVD, MOPP, or MOPP/ABVD hybrid.
  • Patients received a median of four cycles of chemotherapy.
  • Following EPOCH chemotherapy, 7 of 12 patients who responded underwent high-dose chemotherapy with stem cell support.
  • Six out of 14 patients are currently alive, and three had no evidence of disease at the time of last follow-up.
  • Toxicity with EPOCH chemotherapy consisted mainly of myelosuppression, and most patients were managed on an outpatient basis.
  • CONCLUSION: This multicenter community study confirms the activity of EPOCH chemotherapy in the treatment of patients with relapsed Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Prednisone / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11675520.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


48. Macann A, Bredenfeld H, Müller RP, Diehl V, Engert A, Eich HT: Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. Int J Radiat Oncol Biol Phys; 2008 Jan 1;70(1):161-5
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group.
  • PURPOSE: To evaluate the effect of radiotherapy on the severe pulmonary toxicity observed in the pilot study of BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine) for advanced-stage Hodgkin's lymphoma.
  • METHODS AND MATERIALS: Patients with Stage III or IV Hodgkin's lymphoma or Stage IIB with risk factors participated in this single-arm, multicenter pilot study.
  • The pulmonary toxicity occurred either during or immediately after the BAGCOPP chemotherapy course.
  • Pulmonary toxicity contributed to one early fatality but resolved in the other 7 patients after cessation of gemcitabine and bleomycin, allowing continuation of therapy.
  • Gemcitabine (when administered without bleomycin) remains of interest in Hodgkin's lymphoma and is being incorporated into a new German Hodgkin's Lymphoma Study Group protocol that also includes consolidative radiotherapy.
  • This study supports the concept of the integration of radiotherapy in gemcitabine-containing regimens in Hodgkin's lymphoma if there is an interval of at least 4 weeks between the two modalities and with a schedule whereby radiotherapy follows the chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lung / drug effects. Lung / radiation effects
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Drug Interactions. Etoposide / administration & dosage. Female. Germany. Humans. Male. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855012.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


49. Zhou L, Wang Q, Feng F: [Treatment of advanced Hodgkin's disease: an analysis of 128 cases]. Zhonghua Zhong Liu Za Zhi; 2000 Jul;22(4):333-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of advanced Hodgkin's disease: an analysis of 128 cases].
  • OBJECTIVE: To explore the rational treatment for advanced Hodgkin's disease.
  • METHODS: A total of 128 patients with advanced Hodgkin's disease was included in this study.
  • They could be divided into 3 groups according to the treatment they received.
  • Patients in group 1 (n = 99) were treated by combination chemotherapy plus radiotherapy.
  • Patients in group 2 (n = 24) were treated by chemotherapy alone.
  • Patients in clinical stage III with no bulky mass, no systemic symptoms, and their tumor was predominantly of lymphocytic or nodular sclerotic type had better long term survival than those in clinical stage IV with bulky mass, systemic symptoms, and with lymphocyte depleting, mixed cellular tumor.
  • Better long term survival was seen in patients who showed complete response to combined chemotherapy and radiotherapy.
  • At least 6 cycles of chemotherapy were needed.
  • CONCLUSION: Combination chemotherapy plus radiotherapy is effective in the treatment of advanced Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CCAAT-Enhancer-Binding Proteins / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Mechlorethamine / therapeutic use. Middle Aged. Prednisone / therapeutic use. Procarbazine / therapeutic use. Transcription Factor CHOP. Transcription Factors / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11778565.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / DDIT3 protein, human; 0 / Transcription Factors; 147336-12-7 / Transcription Factor CHOP; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; MOPP protocol
  •  go-up   go-down


50. Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group: 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2003 May 1;21(9):1734-9
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
  • PURPOSE: This multicenter pilot study assessed the feasibility and efficacy of a time-intensified bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) regimen given in 14-day intervals (BEACOPP-14) with granulocyte colony-stimulating factor (G-CSF) support in advanced Hodgkin's lymphoma.
  • PATIENTS AND METHODS: From July 1997 until March 2000, 94 patients with Hodgkin's lymphoma stage IIB, III, and IV were scheduled to receive eight cycles of BEACOPP-14.
  • Consolidation radiotherapy was administered to regions with initial bulky disease or residual tumor after chemotherapy.
  • RESULTS: All patients were assessable for toxicity and treatment outcome.
  • Chemotherapy could generally be administered on schedule.
  • Dose reductions varied among drugs but were generally low.
  • Four patients had progressive disease.
  • At a median observation time of 34 months, five patients have relapsed, one patient developed a secondary non-Hodgkin's lymphoma, and three deaths were documented.
  • The overall survival and freedom from treatment failure rates at 34 months were 97% (95% confidence interval [CI], 93% to 100%) and 90% (95% CI, 84% to 97%), respectively.
  • On the basis of these results, the German Hodgkin's Lymphoma Study Group will compare the BEACOPP-14 regimen with BEACOPP-21 escalated in a prospective multicenter randomized trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Anemia / chemically induced. Anemia / prevention & control. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Leukopenia / chemically induced. Leukopenia / prevention & control. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Survival. Thrombocytopenia / chemically induced. Thrombocytopenia / prevention & control. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12721249.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


51. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • METHODS AND MATERIALS: During the period 1971 to 1994, 94 patients with clinically staged HD, with favorable prognostic factors, were retrospectively reviewed.
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • There were 27 Stage IA and 67 Stage IIA patients.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • CONCLUSIONS: Careful clinical staging of early, asymptomatic HD patients treated with mantle, splenic, and EFRT may obviate the need for exploratory laparotomy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


52. Liang JA, Shiau YC, Yang SN, Lin FJ, Lin CC, Kao A, Lee CC: Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression. Oncol Rep; 2002 Mar-Apr;9(2):307-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression.
  • The ability of technetium-99m tetrofosmin (Tc-TF) scan to predict chemotherapy response in malignant lymphomas (ML) was compared with the predictive ability of P-glycoprotein (Pgp) and multidrug resistance related protein (MRP) expression.
  • Before chemotherapy, 25 ML patients were enrolled in this study.
  • Chemotherapy response was evaluated in the first 1-2 years after completion of chemotherapy.
  • No significant differences in the incidences of good and poor response results were found for patients with Hodgkin's disease versus non-Hodgkin's lymphoma, with stage I-II versus stage III-IV, with age > 40 versus age < or = 40 years, or with B symptoms versus without B symptoms.
  • Tc-TF scan results, which may represent either Pgp or MRP expression, accurately predict chemotherapy response in patients with ML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma / metabolism. Lymphoma / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. P-Glycoprotein / metabolism. P-Glycoproteins / metabolism. Prednisone / therapeutic use. Radiopharmaceuticals. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11836597.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


53. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Forty-one patients underwent involved-field radiotherapy in conjunction with high-dose chemotherapy and bone marrow or peripheral stem cell transplantation.
  • Thirty-three patients received involved-field radiotherapy prior to stem cell transplantation directed at symptomatic and/or bulky sites; eight patients received involved-field radiotherapy after stem cell transplantation directed at sites of persistent disease.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • RESULTS: There were 124 deaths during the follow-up period, including 17% of the patients treated with involved-field radiotherapy and 44.2% of the patients receiving chemotherapy without involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • Five of the 41 patients treated with involved-field radiotherapy developed toxicity subsequent to treatment.
  • All but one of these patients had been treated with doses greater than 30 Gy.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Female. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Iraj AK: Hodgkin's disease: assessment of treatment and survival rates in Iran. Asian Pac J Cancer Prev; 2004 Oct-Dec;5(4):379-82
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: assessment of treatment and survival rates in Iran.
  • BACKGROUND AND OBJECTIVE: Each year an estimated of 7,500 new cases of Hodgkin's disease are reported in the United States.
  • It is a type of malignancy, where 75% of patients can recover and be cured with modern therapeutic approaches if presentation is in an early stage.
  • The main objective of this investigation was to assess the current situation with the disease in Iran, with determination of 5- and 10-year-survival rates.
  • The information obtained through medical files was organized and the rate of response to treatment and overall survival (OS) were computed.
  • Neck masses were the most common (40%) complaint among new patients, mostly classified as stage III.
  • Complete remission was achieved with the ABVD chemotherapy regimen, included in 37.6% of overall chemotherapy regimens.
  • CONCLUSION: Chemotherapy was a significantly more effective treatment compared to other modalities, and provided complete remission in 52.7% of patients.
  • As general conclusions, early diagnosis, on time management of the patients, and use of appropriate treatment modalities provide significant prevention of mortality in Hodgkin's disease patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Combined Modality Therapy. Cross-Sectional Studies. Disease-Free Survival. Female. Humans. Iran / epidemiology. Male. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15546241.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


55. Das P, Ng AK, Stevenson MA, Mauch PM: Clinical course of thoracic cancers in Hodgkin's disease survivors. Ann Oncol; 2005 May;16(5):793-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical course of thoracic cancers in Hodgkin's disease survivors.
  • BACKGROUND: Hodgkin's disease survivors have a high risk of subsequently developing thoracic cancers.
  • Our goal was to evaluate the prognosis and treatment outcomes of thoracic cancers after Hodgkin's disease.
  • PATIENTS AND METHODS: Thirty-three patients treated for Hodgkin's disease at Harvard-affiliated hospitals subsequently developed small-cell lung carcinoma, non-small-cell lung carcinoma (NSCLC) or mesothelioma.
  • Information was obtained from medical records about the initial treatment for Hodgkin's disease, any salvage therapy, smoking history, and the stage, histology, treatment and survival for thoracic cancers.
  • RESULTS: Of the 33 patients, 29 (88%) had a history of radiotherapy to the thorax, 17 (52%) had received alkylating chemotherapy, and 24 (73%) had a known history of smoking.
  • The median time between diagnosis of Hodgkin's disease and diagnosis of thoracic cancer was 17.3 years (range 1.2-27.9 years).
  • Among patients with NSCLC and a known stage, 85% presented with stage III or stage IV disease.
  • Among patients whose treatment details were available, 40% underwent surgery, 40% received radiotherapy and 65% received chemotherapy.
  • CONCLUSIONS: Most patients with thoracic cancers after Hodgkin's disease have a history of exposure to risk factors and present at an advanced stage.
  • Patients with thoracic cancers after Hodgkin's disease have a poor survival.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802277.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):191-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin's lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce.
  • We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-related HL.
  • Response to chemotherapy, overall survival (OS) and event-free survival (EFS) were recorded.
  • Twenty-one (34%) patients were in stage III and 41 (66%) in stage IV.
  • INTERPRETATION AND CONCLUSIONS: In patients with advanced stage, HIV-related HL, treatment with ABVD together with HAART is feasible and effective.
  • This supports the concept that patients with HIV-related HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Hodgkin Disease / virology. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4-Positive T-Lymphocytes / metabolism. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296568.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


57. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer Lymphoma Group: Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med; 2003 Jun 12;348(24):2396-406
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field radiotherapy for advanced Hodgkin's lymphoma.
  • BACKGROUND: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial.
  • METHODS: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV) to receive either no further treatment or involved-field radiotherapy.
  • Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites.
  • Patients in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites.
  • RESULTS: Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to no further treatment, and 172 to involved-field radiotherapy.
  • Among the 250 patients in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively.
  • CONCLUSIONS: Involved-field radiotherapy did not improve the outcome in patients with advanced-stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy.
  • Radiotherapy may benefit patients with a partial response after chemotherapy.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Massachusetts Medical Society
  • [CommentIn] N Engl J Med. 2003 Jun 12;348(24):2375-6 [12802021.001]
  • [CommentIn] N Engl J Med. 2003 Sep 18;349(12):1187-8; author reply 1187-8 [13679537.001]
  • (PMID = 12802025.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP-ABV protocol
  •  go-up   go-down


58. Fitoussi, Eghbali H, Tchen N, Berjon JP, Soubeyran P, Hoerni B: Semen analysis and cryoconservation before treatment in Hodgkin's disease. Ann Oncol; 2000 Jun;11(6):679-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semen analysis and cryoconservation before treatment in Hodgkin's disease.
  • BACKGROUND: The prophylaxis of the late effects of chemotherapy and radiotherapy has become one of the major concerns in the management of Hodgkin's disease (HD).
  • PATIENTS AND METHODS: To evaluate the semen quality of patients with HD and the outcome of insemination, we reviewed spermograms of patients who underwent SP before any treatment.
  • 2) HD of any stage;.
  • 3) informed about male sterility after HD treatment;.
  • All patients underwent an initial chemotherapy.
  • Pretherapeutic staging of HD revealed 38 stage I (40%), 38 II (38%), 14 III (15%) and 4 IV (4%).
  • The analysis of semen quality and spermatozoid amount according to various parameters failed to find a correlation with stage, B symptoms, age, or biologic data (LDH, WBC, platelets, ESR).
  • CONCLUSIONS: The low rate of success with cryopreserved semen in these cases suggests the need for a more careful design of non-toxic chemotherapy regimens in combined modality treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10942055.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Niitsu N, Okamoto M, Tomita N, Aoki S, Tamaru J, Miura I, Hirano M: Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leuk Lymphoma; 2006 Sep;47(9):1908-14
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
  • A German Hodgkin's lymphoma (HL) study group designed the BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) regimen.
  • In the BEACOPP regimen, treatment intervals were shortened and the dose-intensity was increased compared with those in the ABVD regimen (doxorubicin, bleomycin, vinblastine and darcarbacine), resulting in a long-term disease-free survival rate of approximately 75-80%.
  • Between April 2001 and February 2004, 20 patients with HL of stage IIB or higher who had received no previous treatment were enrolled.
  • The histologic types were mixed cellularity in four cases and nodular sclerosis in 16 cases.
  • The stages were stage IIB in four cases, stage III in 12 cases, and stage IV in four cases.
  • Adverse drug reactions were grade 4 neutropenia in 12 patients, grade 3-4 thrombocytopenia in seven patients, and grade 3 or higher non-hematologic toxicities in two patients (stomatitis in one patient and ALT/AST elevation in one patient).
  • The BEACOPP regimen for advanced-stage HL showed an excellent complete remission rate and high efficacy even in stage III/IV patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Procarbazine / therapeutic use. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065005.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol
  •  go-up   go-down


60. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A, Participating Centers: Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol; 2002 Oct;13(10):1628-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
  • BACKGROUND: An important variable affecting outcome in relapsed and refractory Hodgkin's disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose chemotherapy (HDCT) and autologous stem cell transplantation.
  • Currently, the optimal salvage chemotherapy regimen for these patients is unclear.
  • Since dexamethasone/cisplatin/cytarabine (DHAP) given at 3-4 week intervals has been shown to be very effective in patients with relapsed aggressive non-Hodgkin's lymphoma, we evaluated this regimen given at a median of 16-day intervals in patients with relapsed and refractory HD.
  • PATIENTS AND METHODS: Patients with relapsed or refractory HD were treated with two cycles of DHAP [dexamethasone 40 mg intravenously (i.v.) day 1-4, cisplatin 100 mg/m(2) i.v. as 24-h continuous infusion day 1, and cytarabine 2 g/m(2) i.v.
  • Forty-two percent of the patients had late relapse, 29% early relapse, 12% multiple relapse and 16% primary progressive/refractory disease.
  • The RRs for patients with late, early, multiple and progressive HD were 91%, 93%, 92% and 65%, respectively.
  • Using the chi-square test for independence, remission status (relapsed HD versus progressive HD) and stage at relapse (stage I/II versus stage III/IV) were significant factors for response to DHAP.
  • Neither severe infections nor treatment-related deaths occurred.
  • CONCLUSIONS: A brief tumor-reducing program with two cycles of DHAP given in short intervals supported by G-CSF is effective and well-tolerated in patients with relapsed and refractory HD.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377653.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


61. Lee CK, Aeppli D, Nierengarten ME: The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):169-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience.
  • PURPOSE: To examine the long-term outcome of Stage I, II, and III patients treated with curative radiotherapy for Hodgkin's disease at the University of Minnesota Hospital, with particular focus on long-term treatment-related complications and the need for long-term surveillance after treatment.
  • METHODS AND MATERIALS: A total of 210 Stage I, II, and III patients (98 female, 112 male) treated at the University of Minnesota since 1970 were included in this study.
  • Between 1970 and 1974, 35 high-risk patients (i.e., patients with large mediastinal mass, and/or hilar disease, and/or splenic involvement) and 40 low-risk patients were treated with standard field radiotherapy.
  • Salvage chemotherapy was given to 62 patients who recurred.
  • Long-term complications after treatment were assessed using standardized incidence ratios (SIR) and mortality ratios (SMR), with particular focus on cardiac complications and secondary malignancies.
  • Patients treated for Hodgkin's disease had about 7 times the risk of dying from cardiac problems (SMR = 7.2) and 10 times the risk of dying from a second malignancy (SMR = 10.3) compared to the general population.
  • In terms of absolute risk, Hodgkin's disease would cause seven additional deaths from secondary malignancies per year among 1000 patients and four additional deaths from cardiac problems.
  • CONCLUSION: Hodgkin's disease patients treated successfully with radiotherapy are at an increased risk for developing long-term treatment-related cardiac disease and/or second malignancies.
  • [MeSH-major] Cardiovascular Diseases / etiology. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Analysis of Variance. Cause of Death. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Recurrence. Salvage Therapy. Sex Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924987.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


62. Akoum R, Brihi E, Saade M, Hanna T, Chahine G: Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma. J Cancer Res Ther; 2007 Jul-Sep;3(3):143-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma.
  • BACKGROUND: Abdominal irradiation, as a part of treatment, is often ignored in the management of refractory non-Hodgkin's lymphoma (NHL).
  • OBJECTIVE: To evaluate the efficacy and the toxicity of this approach after failure of chemotherapy.
  • MATERIALS AND METHODS: 27 patients with intraabdominal lymphoma underwent salvage irradiation between 1982 and 2001.
  • The total dose administered to the abdomen was 18-20 Gy at the rate of 1.5-1.8 Gy per daily fraction, followed by a boost to gross disease up to 20 Gy.
  • All patients had previously been heavily pretreated with chemotherapy.
  • Survival rates were significantly better for patients with refractory relapse compared to those with primary refractory lymphoma (P < 0.01).
  • There was no significant difference in terms of response, recurrence, or survival rates between follicular and aggressive types.
  • Out-of-field recurrence occurred more frequently in initial stage III and IV disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Salvage Therapy
  • [MeSH-minor] Abdomen. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079576.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


63. Tarabar O, Tukić L, Stamatović D, Balint B, Elez M, Ostojić G, Tatomirović Z, Marjanović S: [Autologous stem cell transplantation in the treatment of Hodgkin's disease]. Vojnosanit Pregl; 2009 Jul;66(7):571-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous stem cell transplantation in the treatment of Hodgkin's disease].
  • BACKGROUND/AIM: High-dose chemotherapy with autologous stem cell transplantation (ASCT) has shown to produce long-term disease-free survival in patients with chemotherapy-sensitive Hodgkin disease.
  • The aim of the study was to evaluate efficacy of ASCT in the treatment of Hodgkin's disease.
  • METHODS: Between May 1997 and September 2008, 34 patients with Hodgkin's disease in median age of 25 (range 16-60) years, underwent ASCT.
  • Autologous SCT were performed as consolidation therapy in one poor-risk patients with complete response (CR) and in 10 patients in partial remission (PR) after induction chemotherapy (32.5%), for chemosensitive relapse (CSR 1 and CSR 2) in 47% patients and in 20.5% patients with chemoresistant disease (CRD).
  • All except one patient were in stage III/IV, extranodal site of disease had 24 patients and bulky disease had 10 patients.
  • However, when patients undergoing consolidation were analyzed separately from those in CSR, no significant difference in OS and PFS was observed according to the disease status at ASCT.
  • In univariate analysis for OS, PFS i DFS, extranodal site of disease and disease bulk had no predictive value.
  • The main cause of death was Hodgkin's disease.
  • One patient with CRD developed secondary acute myeloid leukemia and died 28 months after the transplantation.
  • CONCLUSION: Autologous SCT is efficient as consolidation therapy in high-risk patients and in chemosensitive relapse, but it has no benefit in patients with chemoresistant disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678583.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


64. Bai CM, Yang T, Xü Y, Zhang W, Liu XL, Zhu YL, Chen SC, Shen T: [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):142-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factors in primary intestinal non-Hodgkin's lymphoma.
  • METHODS: The clinical presentations, pathological features and therapeutic results of 32 primary intestinal non-Hodgkin's lymphoma were retrospectively analyzed.
  • Twenty-one patients (65.6%) were diagnosed as B-cell lymphoma, 15 (46.9%) were diffuse large B-cell lymphoma.
  • Ten patients (31.2%) were diagnosed as T-cell lymphoma and one (3.1%) as histiocytic lymphoma.
  • Twenty-nine patients were treated initially by surgery with or without chemotherapy, 19 of them (59.4%) achieved complete response.
  • Based on Cox multivariate analysis, stage III - IV, B symptoms and T cell phenotype of the disease were the independent adverse prognostic factors (P < 0.05).
  • CONCLUSION: The clinical presentation of primary intestinal non-Hodgkin's lymphoma are not specific clinically.
  • Most of the histological types are diffuse large B-cell type lymphoma.
  • Complete resection combined with chemotherapy may be the best effective approach for treatment of this disease.
  • The prognosis of this disease are correlated with the stage, B symptoms and T cell phenotype.
  • [MeSH-major] Intestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750023.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


65. Dhakal S, Biswas T, Liesveld JL, Friedberg JW, Phillips GL, Constine LS: Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):188-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma.
  • PURPOSE: To evaluate the patterns and timing of initial recurrence in patients with Hodgkin's lymphoma (HL) who subsequently underwent high-dose chemotherapy with autologous stem cell transplantation to enhance our understanding of the natural history of this disease and its modern treatment strategies and to direct approaches to disease surveillance.
  • METHODS AND MATERIALS: The records of 69 patients with HL who had undergone high-dose chemotherapy with autologous stem cell transplantation in our center between May 1992 and June 2006 were analyzed.
  • The patients were segregated according to the initial stage (Stage I-II vs. III-IV).
  • RESULTS: Early-stage HL patients developed a relapse at a median of 2.1 years (range, 0.5-10.3), with 91% of relapses at the initial disease site, 71% of which (65% overall) were only in previously involved sites.
  • Advanced-stage HL patients developed a relapse at a median of 1.5 years (range, 0.6-10.5), with 97% at the initial site, 71% of which (69% overall) were only in previously involved sites.
  • Single-site relapses occurred in 47% of early- vs. 26% of advanced-stage patients, and extranodal relapses occurred in 12% of early- vs. 31% of advanced-stage patients.
  • CONCLUSIONS: Almost all patients with HL who develop relapse and subsequently undergo high-dose chemotherapy with autologous stem cell transplantation initially developed recurrence in previously involved disease sites.
  • Early-stage HL relapses often occurred in single sites, and advanced-stage disease relapses were more likely in multiple and extranodal sites.
  • The interval to recurrence was brief, suggesting that the frequency of screening should be the greatest in the early post-therapy years.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / drug therapy. Hodgkin Disease / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250770.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • The mean follow-up time for chemotherapy was 40 months (range 20-110 months) with an average dose of prednisone of 8.45 g (range 3.20 - 18.50).
  • In 8 cases (44.44%) forage associated with IES was performed as the initial treatment option and 6 of these cases were found to be in Ficat stage II (75%), 1 was found to be in stage III (12.55%) and another in stage IV (12.5%).
  • In 2 cases, the central decompression technique was used (Simple Forage); both were in Ficat stage II.
  • In the other 8 cases, a total hip arthroplasty (THA) was chosen as the initial treatment option, with 3 of these patients in Ficat stage III and 5 in Ficat stage IV.
  • The clinical outcomes (time to postoperative pain, time to radiological failure, and time to arthroplasty from the forage) following surgical management using the forage-biopsy technique with and without internal electrostimulation (IES) were recorded.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • We considered that in Ficat stage III and IV arthroplasty (THA) was the better option.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement, Hip. Decompression, Surgical. Electric Stimulation Therapy. Female. Glucocorticoids / adverse effects. Humans. Male. Middle Aged. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


67. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi: ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol; 2005 Dec 20;23(36):9198-207
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
  • PURPOSE: In this multicenter, prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) and mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine (MOPPEBVCAD), were compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as standard therapy to select which regimen would best support a reduced radiotherapy program, which was limited to < or = two sites of either previous bulky or partially remitting disease (a modification of the original Stanford program).
  • PATIENTS AND METHODS: Three hundred fifty-five patients with stage IIB, III, or IV HL were randomly assigned.
  • Stanford V was more myelotoxic than ABVD but less myelotoxic than MOPPEBVCAD, which had larger reductions in the prescribed drug doses.
  • CONCLUSION: When associated with conditioned and limited (not adjuvant) radiotherapy, ABVD and MOPPEBVCAD were superior to Stanford V chemotherapy in terms of response rate and FFS and progression-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Lomustine / administration & dosage. Male. Mechlorethamine / administration & dosage. Melphalan / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Dec 20;23(36):9058-62 [16314611.001]
  • (PMID = 16172458.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; Q41OR9510P / Melphalan; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; ABVD protocol; MOPPEBVCAD protocol; Stanford V protocol
  •  go-up   go-down


68. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol; 2005 Feb 20;23(6):1103-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
  • PURPOSE: Patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and can be observed without immediate chemotherapy.
  • The goals of this study were to assess the overall response rate (ORR) to rituximab in this patient population and to determine the time-to-progression (TTP) and time-to-subsequent-chemotherapy (TTSC).
  • PATIENTS AND METHODS: Eligible patients had untreated follicular grade 1 NHL, and measurable stage III/IV disease.
  • Patients received rituximab 375 mg/m(2) intravenous weekly x 4 doses and were then followed for response and progression; no maintenance therapy was provided.
  • Fourteen (39%) of 36 patients remain in unmaintained remission, two died without disease progression, and three died with disease progression.
  • Twenty (56%) of 36 patients have disease progression.
  • Eighteen patients have subsequently been treated with chemotherapy, with a median TTSC of 2.3 years (95% CI, 1.6 to not yet reached).
  • CONCLUSION: Rituximab can be safely administered to patients with advanced-stage follicular grade 1 NHL with efficacy and minimal toxicity.
  • This therapy is highly active and offers an acceptable alternative to observation in this patient population.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease Progression. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Neutropenia / chemically induced. Rituximab. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 20;23(6):1056-8 [15657408.001]
  • (PMID = 15657404.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


69. Wilder DD, Ogden JL, Jain VK: Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma. Clin Lymphoma; 2002 Mar;2(4):229-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
  • This phase II study investigated the efficacy of alternating fludarabine/mitoxantrone/ dexamethasone (FMD) with cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) chemotherapy for patients with high tumor burden, follicular non-Hodgkin's lymphoma.
  • All patients had high tumor burden as defined by the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria.
  • Eighty-four percent of patients (73/87) had stage III/IV disease and 99% of patients (86/87) had good performance status.
  • Event-free survival (EFS) was 28.7 months, with time to progression (TTP) at 29 months and time to treatment failure at 41 months.
  • Patients had similar EFS and TTP as patients in the French GELF trial with a shorter duration of chemotherapy.
  • An informal analysis of interferon maintenance therapy suggests that patients who tolerated the immune modifier did better than those who did not.
  • Alternating FMD/CHOP is a feasible and effective therapeutic option for patients with high tumor burden, low-grade non-Hodgkin's lymphoma.
  • While this regimen may not offer dramatic benefit over FMD alone, it is beneficial in those patients for whom a prompt treatment response is needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Prednisolone / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dexamethasone / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11970762.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VAP-cyclo protocol
  •  go-up   go-down


70. Saif MW, Hamilton JM, Allegra CJ: Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease. Leuk Lymphoma; 2000 Oct;39(3-4):421-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease.
  • Varicella zoster (V-Z) infections are common among patients with hematological malignancies, particularly Hodgkin's disease (HD).
  • The common denominator in both HD and V-Z infections is immunosuppression.
  • Most of V-Z infections occur in patients with HD during the remission period, who have mixed cellularity sub-type, with stage III disease and who have received combined chemo-radiation therapy.
  • The authors describe a case of HD who developed V-Z meningitis preceeded by superficial thrombophlebitis of upper extremities during the period of active chemotherapy.
  • [MeSH-major] Hodgkin Disease / virology. Meningitis, Viral / chemically induced. Thrombophlebitis / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Humans. Immunocompromised Host. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342324.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


71. Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE, Kun L, Billet AL, Kaste S, Tarbell NJ, Howard S, Friedmann AM, Hurwitz CA, Young JA, Marcus KC, Rai S, Cowan T, Weinstein HJ: Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol; 2004 Nov 15;22(22):4541-50
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
  • PURPOSE: To evaluate the efficacy of vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) and cyclophosphamide, vincristine, and procarbazine (COP) chemotherapy and response-based, involved-field radiation, a combined-modality regimen that limits doses of alkylating agents, anthracyclines, and radiation, in children with advanced and unfavorable Hodgkin's disease.
  • PATIENTS AND METHODS: From 1993 to 2000, 159 children and adolescents with unfavorable Hodgkin's disease received three alternating cycles (total of six cycles) of VAMP/COP chemotherapy followed by response-based, involved-field radiation therapy: 15 Gy was administered to patients achieving a complete response, and 25.5 Gy was administered to those achieving a partial response after the first two cycles of chemotherapy and to all sites of bulky lymphadenopathy.
  • Unfavorable disease was defined as clinical stage I and II with bulky peripheral nodal disease greater than 6 cm, initial bulky mediastinal mass 33% or more of the intrathoracic diameter, and/or "B" symptoms and all stage III and IV.
  • Disease presentation was localized (stage I/II) in 77 patients (48.4%) and advanced (stage III/IV) in 82 patients (51.6%).
  • CONCLUSION: Risk-adapted combined-modality therapy with VAMP/COP and response-based, involved-field radiation therapy results in an unsatisfactory outcome for pediatric patients with unfavorable presentations of Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Risk Assessment. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542805.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


72. Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS: CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leuk Lymphoma; 2003 Jun;44(6):967-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
  • The role of high dose therapy, including autologous stem cell transplantation (ASCT) in indolent non-Hodgkin's lymphomas remains controversial.
  • We evaluated a dose intense regimen of CHOP induction followed by high dose cyclophosphamide consolidation (CHOP-HC) versus CHOP alone in a prospective comparison to assess intensified therapy without ASCT.
  • Twenty-five patients with previously untreated advanced stage indolent NHL were enrolled: follicular lymphoma, grade 1 (11 patients) and grade 2 (8 patients); small lymphocytic lymphoma (5 patients); and lymphoplasmacytic lymphoma (1 patient).
  • Three patients had intra-abdominal stage II, 2 patients with stage III, and 20 patients with stage IV disease.
  • Following induction, responding patients were given consolidation with either high dose cyclophosphamide @ 3 gm/m2 i.v. for 3 doses with G-CSF (weeks 13, 15, 17) or 2 additional cycles of CHOP (weeks 13, 16), stratified by stage and bulk of disease.
  • There were no treatment-related deaths.
  • With no obvious improvement in CR and with greater hematologic toxicity than CHOP, CHOP-HC is not recommended for treatment of indolent non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Rate. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down


73. Navarro JT, Ribera JM, Oriol A, Xicoy B, Mate JL, Sirera G, Lloveras N, Millá F, Feliu E: Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy. Int J Hematol; 2007 Nov;86(4):337-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
  • In the era of highly active antiretroviral therapy (HAART), the prognosis for acquired immunodeficiency syndrome-related lymphomas (ARL) seems to be similar to that for aggressive B-cell lymphomas in human immunodeficiency virus (HIV)-negative patients.
  • We evaluated the prognostic factors for response and survival in a series of HIV-infected patients with systemic non-Hodgkin's lymphoma (NHL) in the HAART era.
  • Forty patients with systemic NHL treated with a CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and HAART were studied.
  • Patients were scheduled to receive cycles of CHOP therapy, and all received granulocyte colony-stimulating factor.
  • The 5-year disease-free survival (DFS) probability (95% confidence interval [CI]) was 73% (54%-92%).
  • The median overall survival (OS) time was 69.17 months, and the 5-year OS rate (95% CI) was 51% (35%-67%).
  • A disease stage of III to IV was the only parameter with prognostic influence on DFS.
  • The factors influencing OS were an International Prognostic Index >2, an Eastern Cooperative Ecology Group (ECOG) score >2, and a disease stage of III to IV.
  • Patients with an advanced stage had a lower OS probability in a multivariate analysis (odds ratio, 4.24; 95% CI, 1.24- 14.57).
  • Advanced stage was the main prognostic factor predicting survival in ARL treated with CHOP and HAART.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / pathology. Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. HIV / physiology. Humans. Male. Prednisolone. Prognosis. Vincristine

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] AIDS. 2001 Aug 17;15(12):1483-91 [11504980.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Biometrics. 1973 Sep;29(3):579-84 [4793138.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • [Cites] AIDS. 2002 Sep 27;16(14):1973-6 [12351963.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1837-42 [12685841.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1891-7 [15550484.001]
  • [Cites] AIDS. 2000 Aug 18;14(12):1675-88 [10985303.001]
  • [Cites] Leuk Lymphoma. 1995 Dec;20(1-2):91-6 [8750628.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):909-15 [11298585.001]
  • [Cites] Am J Med. 1993 Aug;95(2):188-96 [7689296.001]
  • [Cites] Haematologica. 2003 Apr;88(4):445-53 [12681972.001]
  • [Cites] Haematologica. 2005 May;90(5):704-6 [15921395.001]
  • [Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):142-4 [14679461.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4423-7 [14581441.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8477-82 [16230675.001]
  • (PMID = 18055341.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


74. Schumacher YO, Muser K, Hirschberger B, Roecker K, Dickhuth HH, Pottgiesser T: Hodgkin's Lymphoma in an elite endurance athlete. Med Sci Sports Exerc; 2008 Mar;40(3):401-4
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's Lymphoma in an elite endurance athlete.
  • He was subsequently diagnosed with stage III A (S) Hodgkin's lymphoma.
  • Immediately after six courses of escalated BEACOPP chemotherapy in an identical test setting, aerobic capacity was markedly reduced (-42%), mainly because of a decrease in total hemoglobin mass (-37%), despite maintaining a certain amount of endurance training.
  • Two months after chemotherapy, the athlete had recovered his hemoglobin mass, and his aerobic performance was almost back to pretherapy levels.
  • This case illustrates that advanced malignancies can be present in elite athletes without affecting performance, and that aerobic capacity can be regained within a short time after systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / diagnosis. Sports
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Germany. Hemoglobins / analysis. Humans. Male. Physical Endurance. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379199.001).
  • [ISSN] 0195-9131
  • [Journal-full-title] Medicine and science in sports and exercise
  • [ISO-abbreviation] Med Sci Sports Exerc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


75. Balwierz W, Moryl-Bujakowska A, Depowska T, Klekawka T, Rokicka-Milewska R, Sopylo B, Kolakowska-Mrozowska B, Chybicka A, Boguslawska-Jaworska J, Pisarek J, Ras M, Sonta-Jakimczyk D, Janik-Moszant A, Kolecki P, Kaczmarek-Kanold M, Kowalczyk J, Odoj T, Matysiak M, Newecka-Samol T, Balcerska A, Adamkiewicz-Drozynska E, Wysocki M, Kurylak A: [Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy]. Med Wieku Rozwoj; 2001 Jul-Sep;5(3 Suppl 1):25-35
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy].
  • Between 1997 to 1999 in 9 centres of the Polish Paediatlic Leukemia/Lymphoma Study Group, 167 children and adolescents (aged 2-19 years) with stage 1 to IV Hodgkin's disease (HD) were treated according to a regimen with a limited use of radiotherapy (RT).
  • All patients received B-DOPA and MVPP chemotherapy.
  • The number of cycles of chemotherapy was adjusted in respective risk groups.
  • In 13 children with stage IA and IIA disease with favourable prognostic factors chemotherapy alone was used.
  • In other patients the dose of RT applied to lymphatic regions was 15-46,4 Gy.
  • In case of a small tumour at presentation and good response to initial chemotherapy the RT dose was 15-16 Gy.
  • In other cases doses of 25-30 Gy were planned.
  • The use of higher doses, particularly exceeding 35 Gy, in eleven patients, was not justified.
  • Among all the 167 patients, three oftliem (1.2%) with advanced disease (Stage III-1V) did not achieve first remission.
  • All 13 children in whom chemotherapy alone was used remain in first remission.
  • In the group of children who received RT in the dose of 15-16 Gy relapse occurred in one child.
  • Our preliminary analysis indicates that limited use of RT in selected cases of HD in children and adolescents did not show worse results of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Remission Induction. Risk. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004149.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


76. Brown HG, Whiting DM, Prostko ER, Fox KR, Zhang J: January 2001: A 37 year old man with a history of Hodgkin's disease. Brain Pathol; 2001 Jul;11(3):387-8; 393
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] January 2001: A 37 year old man with a history of Hodgkin's disease.
  • The January Cases of the Month (COM): A case of intracranial metastatic nodular sclerosing Hodgkin's disease without dural attachment in a 37-year-old previously stage III male is presented with a brief review of the literature.
  • Both the primary tumor in the lymph node biopsy and the metastatic brain tumor showed similar histopathology and a immunohistochemical profile typical for Hodgkin's Disease.
  • After chemotherapy, there are no signs of recurrence or systemic disease on follow-up for five months.
  • [MeSH-major] Hodgkin Disease / radionuclide imaging. Parietal Lobe / radionuclide imaging
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Humans. Male. Neoplasm Proteins / analysis. Reed-Sternberg Cells / chemistry. Reed-Sternberg Cells / pathology. Syncope / etiology. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11414479.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


77. Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, Grotenhermen FJ, Tesch H, Bredenfeld H, Koch P, Nisters-Backes H, Wolf J, Engert A, Diehl V: Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol; 2001 Sep;12(9):1307-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.
  • Infertility after treatment of patients with Hodgkin's disease (HD) is considered as a side effect of alkylating agent containing chemotherapy regimens.
  • To investigate whether gonadal failure is related primarily to the toxic effect of chemotherapy or rather to the disease itself, we investigated the fertility status before the onset of treatment.
  • PATIENTS AND METHODS: Semen quality and hormonal status were evaluated in 158 patients with first diagnosis of HD enrolled into trials of the German Hodgkin Lymphoma Study Group (GHSG).
  • Twenty patients (13%) were classified as early stage HD, 63 patients (40%) as intermediate stage, and 75 patients (47%)) as advanced stage according GHSG grading.
  • RESULTS: Prior to treatment, severe damage of fertility, i.e.. azoospermia and oligoasthenoteratospermia (OAT-syndrome) was found in 13 (8%) and 20 patients (13%), respectively.
  • Thus, III patients (70%) showed semen abnormalities before the onset of treatment.
  • In a multivariate analysis elevated ESR (P < 0.003) and advanced stage of disease (P < 0.01) could be distinguished as prognostic factors for severe damage of fertility.
  • No correlation was found between pre-therapeutic gonadotropine levels and fertility status.
  • CONCLUSION: Patients with HD have an increased risk for inadequate semen quality even prior to treatment.
  • Infertility is more frequent in patients with elevated ESR and advanced stage of disease.
  • This association demonstrates the predominant influence of the disease on fertility.
  • Assuming HD is the major initial cause for infertility efforts should be made to identify new non-gonadal toxic chemotherapies to be able to regain fertility after effective therapy.
  • Further investigations have to be performed to clarify mechanisms inducing fertility defects in patients with HD.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2002 Feb;13(2):333 [11886015.001]
  • (PMID = 11697845.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


78. Straus DJ: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res; 2002;159:143-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.
  • Chemotherapy regimens similar to those used for non-Hodgkin's lymphoma (NHL) not associated with human immunodeficiency virus (HIV) infection have been used for patients with HIV-associated NHL with less success.
  • In a recent trial, patients with intermediate or high-grade NHL were randomized to either low-dose chemotherapy with methotrexate, bleomycin, doxorubicin, vincristine and dexamethasone (m-BACOD) or to standard-dose m-BACOD with sargramostim (granulocyte-macrophage colony-stimulating factor, GM-CSF).
  • Myelosuppression was greater with standard-dose chemotherapy.
  • In univariate and multivariate analyses of 21 pretreatment features of patients in this trial, four factors emerged as adversely prognostic with respect to survival: age >35 years, intravenous drug use, CD4 counts < 100/mm3 and stage III/IV disease.
  • The outcome of these patients may be improving with the use of highly active antiretroviral therapy (HAART), which seems to improve immune function and tolerance of chemotherapy.
  • A recent trial of the AIDS Malignancy Consortium found that low-dose chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone: CHOP) and standard-dose chemotherapy had similar response rates, acceptable toxicity and minimal alterations in cyclophosphamide, doxorubicin and indinavir pharmacokinetics in HIV-associated lymphoma patients also on HAART (stavudine, lamivudine and indinavir).
  • There is a suggestion that Burkitt-type lymphomas may tend to occur in HIV-infected patients with relatively well preserved immune function and CD4 cell counts.
  • Recent results from our institution suggest that similar outcomes are achievable with intensive chemotherapy in patients with Burkitt's lymphomas with or without HIV infection.
  • With improved immune status and improved bone marrow function with the use of HAART, it will probably become more possible to treat many patients with aggressive HIV-associated NHL with more intensive treatment regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Humans. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785838.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


79. Murtha AD, Rupnow BA, Hansosn J, Knox SJ, Hoppe R: Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys; 2001 Jan 1;49(1):3-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University.
  • PURPOSE: To report the long-term survival and late toxicity data of Stage III follicular lymphoma patients treated with primary radiotherapy.
  • METHODS AND MATERIALS: Sixty-six patients with Stage III follicular small cleaved (FSC) or follicular mixed (FM) non-Hodgkin's lymphoma were treated with total lymphoid irradiation (61 patients) or whole body irradiation (5 patients) as their primary treatment modality from 1963 to 1982 at Stanford University.
  • Adjuvant chemotherapy was given to 13 patients.
  • Few initial relapses or lymphoma-related deaths were seen beyond the first decade of follow-up.
  • Patient age and number of disease sites were the two strongest predictors of overall survival.
  • The cohort of patients with limited Stage III disease demonstrated an 88% freedom from relapse and a 100% cause-specific survival with up to 23.5 years follow-up.
  • CONCLUSION: The long-term survival data for Stage III FSC or FM non-Hodgkin's lymphoma treated with primary radiotherapy are at least comparable and possibly better than results achieved with other therapeutic approaches.
  • Patients with limited Stage III disease do particularly well.
  • Whether these results are superior to an initial approach of deferred therapy until clinically indicated is currently unknown.
  • [MeSH-major] Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Irradiation. Male. Middle Aged. Neoplasm Staging. Recurrence. Survival Analysis. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):1-2 [11163491.001]
  • [ErratumIn] Int J Radiat Oncol Biol Phys 2001 May 1;50(1):285
  • (PMID = 11163492.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • Of the 89 patients, 58 (72%) received radiochemotherapy, 19 (21%) received radiotherapy alone, 3 received chemotherapy alone, and 1 received radiochemotherapy combined with rituximab.
  • The 5-year overall survival rate was 80%, that of stage I-II patients was 84%.
  • Cox regression multivariate analysis showed that the survival rate was correlated to the value of international prognostic index (IPI), and whether the patient had primary refractory or relapsed disease, but was not correlated to sex, age, pathologic subtype, B symptoms, and bulky disease.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


81. Rygoł B, Kyrcz-Krzemień S, Pajiak J, Konicki P, Kowai E, Gasińska T: [Tryptase- and chymase-positive mast cells as possible prognostic factor in patients with Hodgkin's lymphoma]. Pol Arch Med Wewn; 2007 Jan-Feb;117(1-2):27-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tryptase- and chymase-positive mast cells as possible prognostic factor in patients with Hodgkin's lymphoma].
  • Aim of the study was to reveal potential prognostic factors in Hodgkin's lymphoma (HL) patients by means of assessment of the influence of mast cells on clinical characteristics of the disease.
  • PATIENTS AND METHODS: Paraffin-fixed lymph node biopsies taken from the group of 72 patients treated for Hodgkin's lymphoma in the Department of Internal Medicine and Oncological Chemotherapy of Silesian Medical Academy in Katowice from 1990 to 2002.
  • The analyzed group consisted of 44 men (age 16-73, mean 39.2) and 28 women (age 15-73, mean 36.5) presenting with 5 histological types of HL according to WHO classification.
  • Overall survival (OS) for the group ranged from 3 to 169 month (mean 64.5) while disease-free survival (DFS) was from 4 to 167 months (mean 44.8).
  • Tryptase and chymase-positive mast cell density was assessed in order to correlate it with histological type, staging, sex and age of patients.
  • Tissue specimens were immunohistochemically stained for mast cell tryptase and counted at 200x magnification.
  • RESULTS: The highest density of MCD-T and MCD-C was observed in NS type while the lowest characterized LD.
  • Despite the fact that increased density of MCD-T and MCD-T was observed in stage III and the lowest in stage IV of the disease, no correlation was found between MCD and stage, sex or age.
  • Overall survival was assessed in correlation with histological type and showed to be longest in MC and worst in NS type.
  • CONCLUSIONS: Tryptase and chymase-positive mast cell density is related to histological type of Hodgkin's lymphoma.
  • [MeSH-major] Biomarkers, Tumor. Chymases / metabolism. Hodgkin Disease / enzymology. Hodgkin Disease / mortality. Mast Cells / enzymology. Tryptases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis. Disease-Free Survival. Humans. Immunohistochemistry. Lymph Nodes / cytology. Lymph Nodes / enzymology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642203.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


82. Akcali Z, Ozyilkan O, Moray G, Emiroglu R, Haberal M: Treatment results in renal transplant recipients with non-Hodgkin's lymphoma. Transplant Proc; 2003 Jun;35(4):1404-7
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results in renal transplant recipients with non-Hodgkin's lymphoma.
  • The purpose of this study was to investigate the incidence of non-Hodgkin's lymphoma (NHL), response to treatment, and survival time in renal transplant recipients at our center who developed this form of neoplasia.
  • Complete remission was achieved in eight cases, and five of these individuals were still alive at the time of writing.
  • (1) progressive gastric adenocarcinoma 9 years after being diagnosed with NHL, (2) stage III NHL cured with chemotherapy, but died of infection 2 years after NHL diagnosis, and (3) recurrent intestinal lymphoma, with death during second line chemotherapy.
  • The median time from transplantation to diagnosis of NHL was 66 months.
  • At the time of writing, the median survival time for the eight patients who achieved complete remission was 41.5 months.
  • The study showed that treatment of localized disease (skin or intestinal NHL) with surgery and/or radiotherapy/chemotherapy leads to complete remission and long survival times; however, patients in remission are at risk for other causes of death.
  • [MeSH-major] Kidney Transplantation / statistics & numerical data. Lymphoma, Non-Hodgkin / epidemiology. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Cadaver. Female. Humans. Incidence. Living Donors. Male. Middle Aged. Survival Analysis. Time Factors. Tissue Donors. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12826172.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Gershanovich ML, Kanaev SV, Filatova LV, Novikov SN, Leenman EE, Pozharisskiĭ KM: [Clinical course and treatment of Hodgkin's disease with concomitant bone marrow lesions]. Vopr Onkol; 2002;48(1):29-36
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course and treatment of Hodgkin's disease with concomitant bone marrow lesions].
  • [Transliterated title] Osobennosti kliniki i lecheniia bol'nykh limfomoĭ Hodgkin-a s porazheniem kostnogo mozga.
  • Fifty patients with confirmed local multiple lesions of bone marrow were selected by 99mTc scintigraphy, magnetic resonance imaging and morphologically-supported trepan biopsy from 155 cases of Hodgkin's disease stage II-IVAB.
  • Bone marrow lesions were relatively more common in younger patients 1-11 months after primary tumor detection (an average of 6.5 months).
  • They were detected within 12-156 months (an average of 48 months) among relapsing patients with nodal sclerosis and mixed-cell tumors stage III-IVAB, mostly concomitant with anemia and lymphopenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / drug therapy. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Female. Humans. Interleukin-1 / therapeutic use. Leukocytes / drug effects. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101562.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Interleukin-1
  •  go-up   go-down


84. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F: Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma; 2001 May;41(5-6):535-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome.
  • We report the frequency, presenting characteristics, progression-free survival, event-free survival, overall survival and AIDS-free survival of patients with previously untreated Hodgkin's disease (HD) in the setting of infection by human immunodeficiency virus (HIV).
  • Anderson Cancer Center between July 1985 and August 1999 with HD and HIV infection.
  • All available records were reviewed to determine presentation, clinical characteristics, treatment outcome, progression-free survival and overall survival.
  • We identified 887 patients with HD and 3,500 with Non-Hodgkin's Lymphoma (NHL).
  • The ratio of NHL to HD in HIV-negative versus HIV-positive patients was 3.9 versus 6.9, respectively.
  • There were 14 HIV-positive patients with HD and 97 with NHL.
  • The median age of the HIV-positive HD patients was 33 years, and 13 were male.
  • Three patients had Acquired Immune Deficiency syndrome (AIDS) at the time of HD diagnosis, and seven had B-symptoms.
  • Ann Arbor stage was I in one, II in three, III in four and IV in six patients.
  • Mixed cellularity histology was seen in eight, bone marrow involvement in five and extranodal disease in seven patients.
  • All patients received some antiretroviral therapy, but it was variable over the years.
  • Six patients died of complications arising from HIV infection, including one patient who had preexisting AIDS at HD presentation.
  • Two patients died of HD, without developing other conditions diagnostic of AIDS.
  • We conclude that in our referral patient population HIV infection is associated with preferential development of NHL rather than HD, which appears curable with standard treatment regimens.
  • Since HIV-related deaths exceed those caused by HD, future investigation should focus on integration of chemotherapy and highly active antiretroviral therapy.
  • [MeSH-major] Hodgkin Disease / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Actuarial Analysis. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiviral Agents / administration & dosage. Female. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378571.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


85. Todisco M, Casaccia P, Rossi N: Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial. Cancer Biother Radiopharm; 2001 Apr;16(2):171-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial.
  • This provided the rationale to conduct, in patients with low-grade non-Hodgkin's lymphomas (NHL), a phase II trial of a combined association of cyclophosphamide, somatostatin, bromocriptin, retinoids, melatonin and ACTH.
  • PATIENTS AND METHODS: Twenty patients with a diagnosis of low-grade NHL, stage III or IV, were included in this study.
  • Patients received for one month the following treatment: cyclophosphamide, somatostatin, bromocriptin, retinoids, melatonin, and ACTH.
  • The therapy was continued for two additional months in patients with stable or responding disease.
  • After three months, the responding patients continued the therapy for three months and more.
  • RESULTS: Twenty patients were assessable for toxicity and response; 70% (14 of 20 patients; 95% confidence interval [CI], 50% to 90%) had a partial response; 20% (4 of 20) had stable disease, and 10% (2 of 20) progressed on therapy.
  • Going on with the treatment, none of the 14 patients with partial response had a disease progression (average follow-up time of 21 months, range, 7 to 25), and 50% of these patients had a complete response; among 4 patients with stable disease, 25% (1 of 4) had a partial response and 75% (3 of 4) progressed on therapy (mean time to progression [TTP] 14.3 months, range, 7 to 21).
  • CONCLUSIONS: The association of cyclophosphamide, somatostatin, bromocriptin, retinoids, melatonin, and ACTH is well tolerated and effective in treatment of low-grade NHL at advanced stage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adrenocorticotropic Hormone / administration & dosage. Adult. Aged. Antioxidants / administration & dosage. Bromocriptine / administration & dosage. Cyclophosphamide / administration & dosage. Drug Evaluation. Female. Humans. Male. Melatonin / administration & dosage. Middle Aged. Retinoids / administration & dosage. Somatostatin / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MELATONIN .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11385964.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Retinoids; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 8N3DW7272P / Cyclophosphamide; 9002-60-2 / Adrenocorticotropic Hormone; JL5DK93RCL / Melatonin
  •  go-up   go-down


86. Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ: [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):391-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
  • OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL).
  • 4% (67/121) had early disease (stage I or II), and 89.3% (108/121) had IPI score 0-2.
  • The overall response (OR) rate in this series was 90.9% (110/121) with a complete remission (CR) rate of 71.9% (87/121); whereas the response rate of chemotherapy alone was 88.4% (107/121) with a CR rate of 67.8% (82/121).
  • Major toxicity consisted of grade III-IV myelosuppression (11.9%), neutropenia (1.9%) and thrombocytopenia and anemia (1.1%).
  • The overall 1-, 3- and 5-year survival rate was 84.8%, 62.7% and 55.9%, respectively, with a median survival time of 85 months (2-118 months).
  • CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Child. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892140.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


87. Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol; 2006 Jun;17(6):914-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
  • BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART).
  • MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004.
  • RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness.
  • Fifty-nine of 66 patients (89.4%) underwent curative intended chemotherapy.
  • Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33).
  • CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565210.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


88. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol; 2002 Jan 01;20(1):221-30
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
  • PURPOSE: To evaluate salvage treatment outcome of patients with relapsed Hodgkin's disease (HD) and to distinguish different risk groups using identified prognostic factors.
  • PATIENTS AND METHODS: From 4,754 patients registered in the German Hodgkin's Lymphoma Study Group (GHSG) database between 1988 and 1999, 422 patients with early (n = 170) or late (n = 252) relapsed HD were identified.
  • One hundred seven patients (25%) relapsed after radiotherapy (RT) for early stages, 133 patients (32%) after combined-modality therapy for intermediate stages, and 182 patients (43%) after chemotherapy (CT) and RT to initial bulky disease or residual lymphoma for advanced stages.
  • At relapse, characteristics of these 422 patients (median age, 38 years; range, 17 to 77) were stage III/IV, 45%; B symptoms, 24%; elevated erythrocyte sedimentation rate, 29%; anemia, 13%; and Karnofsky performance score, less than 90 in 13%.
  • At first relapse, salvage treatment was RT in 13%, CT in 54%, and high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) in 33%.
  • RESULTS: Median follow-up time after relapse was 45 months.
  • In multivariate analysis, independent risk factors were time to relapse, clinical stage at relapse, and anemia at relapse.
  • CONCLUSION: In the GHSG database, time to relapse and clinical stage and anemia at relapse are relevant factors and can be used to form a prognostic score for HD patients at relapse.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Salvage Therapy
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Analysis of Variance. Combined Modality Therapy. Female. Follow-Up Studies. Germany / epidemiology. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Recurrence. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11773173.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P: Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol; 2000 Mar;18(5):972-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.
  • PURPOSE: This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy to bulky Hodgkin's disease sites.
  • PATIENTS AND METHODS: A two-stage design was implemented in a phase II study involving 47 patients with bulky mediastinal stage I/II or stage III/IV Hodgkin's disease.
  • Twelve weeks of the Stanford V chemotherapy regimen were given with consolidative radiotherapy (36 Gy) to lymph nodes >/= 5 cm and/or macroscopic splenic disease.
  • Treatment was administered in one of five institutions participating in the Eastern Cooperative Oncology Group.
  • RESULTS: With a median follow-up of 4.8 years, 45 patients are alive and 40 have been continuously disease-free.
  • There was one death from Hodgkin's disease and one death from an M5 acute leukemia.
  • Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantation.
  • CONCLUSION: Stanford V chemotherapy and consolidative radiotherapy to bulky disease is effective in bulky and advanced Hodgkin's disease in a multi-institutional setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Quality Control. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10694546.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636; etc
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


90. Gao Y, Li Y, Yuan Z, Zhao L, Liu X, Gu D, Qian T, Yu Z: [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):483-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil].
  • OBJECTIVE: To investigate the prognostic value of the size of primary tumor (T staging) and international prognostic index (IPI) for patients with non-Hodgkin's lymphoma (NHL) of the tonsil, and to recommend the treatment strategy for early stage patients.
  • According to Ann Arbor staging classification, 35 patients had stage I, 178 stage II, 49 stage III and 44 stage IV disease.
  • According to 1997' AJCC staging system, 29 patients had T1, 142 T2, 117 T3 and 18 T4 disease.
  • Twelve stage I patients were given radiotherapy alone and 23 stage II patients were given combined modality therapy (CMT).
  • For patients with stage II lesion, 57 were given radiotherapy alone, 2 chemotherapy alone and 119 CMT.
  • Chemotherapy was the main treatment in patients with stage III or IV lesions.
  • RESULTS: The 5-year cancer specific survival (CSS) was 74% for patients with T(1), 59% for T(2), 56% for T(3) and 26% for T(4), respectively (P = 0.000).
  • CMT significantly improved disease free survival (DFS) from 46% (radiotherapy alone) to 60% (CMT) for stage II patients (P = 0.046).
  • Combined modality therapy significantly improves the disease free survival of stage II patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Tonsillar Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485504.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


91. Chisesi T, Polistena P, Contu A, Coser P, Indrizzi L, Leoni P, Majolino I, Porcellini A, Salvagno L, Zambaldi G, Rizzoli V, Congiu AM, Santini G, Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG): Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients. Leuk Lymphoma; 2001 Mar;41(1-2):125-36
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
  • Here we report the results of a randomised multicenter phase III clinical trial which assesses the therapeutic efficacy and tolerability of a chemotherapy protocol CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) in adult and elderly patients with advanced intermediate and high-grade NHL.
  • Between October 1991 and October 1995, 139 patients, aged 55 to 79 years, with diffuse intermediate and high-grade lymphoma, were enrolled.
  • A considerable percentage of patients had clinically aggressive disease: 32.4% had systemic symptoms, 79% had stage III or IV disease, 33.8% had bone marrow involvement, 46% had splenic involvement and 42.5% had increased values of serum lactate dehydrogenate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Age Factors. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cyclophosphamide / toxicity. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / standards. Etoposide / toxicity. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / standards. Mitoxantrone / toxicity. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342364.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CEMP protocol
  •  go-up   go-down


92. Kochbati L, Boussen H, Benna F, Belhaj Ali Z, Gammoudi A, Bouaouina N, Besbes M, Ghilen L, Rahal K, Maalej M: [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz]. Cancer Radiother; 2003 Oct;7(5):302-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
  • [Transliterated title] Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie. Etude rétrospective à propos de 26 cas observés à l'institut Salah-Azaïz.
  • PURPOSE: To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.
  • METHODS AND PATIENTS: We consider as second cancer all tumours other than HD observed in patients after treatment for HD.
  • RESULTS: Twenty-five patients among 614 treated for HD between 1975 and 1991 developed 26 secondary tumours (4.2%).
  • Mean age at the diagnosis of HD was 32.5 years (12-56).
  • HD was stage II (eight cases), stage III (14) and stage IV in three.
  • The first treatment was combined chemotherapy and radiotherapy in 22 cases and only chemotherapy in three cases (stage IV).
  • Mean dose was 41.3 Gy (2 Gy/fraction in 21 and 3.3 in one).
  • Chemotherapy was MOPP (13), MOPP and vinblastine (four), MOPP-ABVD (five), ABVD (two) and vinblastine only in one.
  • There was five acute myeloid leukaemia, two digestive non-Hodgkin lymphomas, five nodal high-grade lymphomas, three breast cancers (one in man associated with thyroid cancer), five lung cancers (three non-small cell and two of small cell type), two gastric tumours and one rectal cancer, one synovialosarcoma of the knee and one malignant Schwannoma of the neck.
  • CONCLUSION: Second cancer risk after treatment for HD is not low.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Incidence. Male. Mechlorethamine / adverse effects. Middle Aged. Prednisone / adverse effects. Procarbazine / adverse effects. Retrospective Studies. Risk Factors. Tunisia / epidemiology. Vinblastine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522350.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


93. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V: Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant; 2002 Feb;29(4):285-90
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
  • Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in non-Hodgkin's lymphoma (NHL) patients.
  • Sixty-four patients (88.9%) had stage III-IV disease.
  • Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m(2)) in 34 (47.2%) and the results of 132 procedures were analyzed.
  • At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy).
  • Pre-apheresis CD34+ blood cell count and number of previous chemotherapy treatments were used to predict the total number of CD34+ cells in the apheresis product.
  • Since DHAP was very effective as salvage treatment, we suggest using DHAP as a mobilizing regimen in patients with active residual lymphoma at the time of stem cell collection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Cisplatin. Cyclophosphamide / administration & dosage. Cytarabine. Dexamethasone. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Hematopoietic Stem Cell Transplantation. Humans. Leukocyte Count. Male. Middle Aged. Prospective Studies. Transplantation, Autologous

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11896424.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


94. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • The overall treatment consisted of both EFRT and CHT.
  • The daily dose was 1.5-2 Gy, the total dose for EFRT was 20-40 Gy.
  • RESULTS: Follow-up extended from a minimum of 0,3 years to maximum 25,7 years, with a median observation time 12 years.The 5-, 10-, 15-, and 25-year overall survival (OS) in the whole group was 93% : 86% : 82% : 82%, respectively.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • In multivariate analysis, independent risk factors age < or = 15 years (p < 0.001), male gender (p = 0.005), daily dose < or = 1.5 Gy (p = 0.009), and total dose 26-30 Gy (p = 0.048) were found to positively affect OS.
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


95. Validire P, Fermé C, Brice P, Diviné M, Gabarre J, Bouabdallah K, Fitoussi O, Chaoui D, Pacquement H, Soussain C, Carde P, Salhi R, Zanni M, Decaudin D: A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients. Anticancer Drugs; 2008 Mar;19(3):309-15
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.
  • The aim of this study was to assess the efficacy of a gemcitabine-containing regimen in pretreated Hodgkin's lymphoma (HL) patients.
  • Initial characteristics before gemcitabine administration were: Ann Arbor stage III-IV: 84%; International Prognostic Score less than 3 in 18/39 cases (46%); 31 primary refractory patients at the end of first-line therapy (56%); median number of previous chemotherapy regimens of 3.
  • Gemcitabine was administered at a maximal dose of 1000 mg/m2 per injection (range: 650-1250) in combination with vinorelbine in 10 patients, oxaliplatin in 13 patients, and other drugs in three patients, with a median of six injections (range: 1-18).
  • On univariate analysis, two adverse factors at progression were significant for response to gemcitabine-based regimen: stage III-IV disease and hemoglobin level was less than 10.5 g/dl.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Hemoglobins / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510178.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


96. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol; 2006 Sep 1;24(25):4116-22
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
  • PURPOSE: To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD).
  • PATIENTS AND METHODS: We developed a decision-analytic model to evaluate follow-up strategies for two hypothetical cohorts of 25-year-old patients with stage I-II or stage III-IV HD, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine-based chemotherapy with or without radiation therapy, respectively.
  • With adjustments for quality of life, we found a decrement in quality-adjusted life expectancy for early-stage patients followed with CT compared with non-CT modalities.
  • For advanced-stage patients, annual CT for 5 years is associated with a very small quality-adjusted survival gain over non-CT follow-up with an incremental cost-effectiveness ratio of 9,042,300 dollars/QALY.
  • CONCLUSION: Our analysis suggests that routine CT should not be used in the surveillance of asymptomatic patients in CR after treatment for HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decision Support Techniques. Hodgkin Disease / economics. Hodgkin Disease / radiography. Population Surveillance / methods. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Life Expectancy. Markov Chains. Neoplasm Staging. Predictive Value of Tests. Quality-Adjusted Life Years. Sensitivity and Specificity. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943528.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R25 CA57711-11
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


97. Bariakh EA, Zvonkov EE, Kremenetskaia AM, Kravchenko SK, Magomedova AU, Obukhova TN, Samoĭlova RS, Vorob'ev IA, Kaplanskaia IB, Moiseeva TN, Zybunova EE, Lorie IuIu, Chernova NG, Mar'in DS, Egorova EK, Krasil'nikova BB, Gabeeva NG, Vorob'ev AI: [Treatment of adult Berkitt-like lymphoma]. Ter Arkh; 2005;77(7):53-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult Berkitt-like lymphoma].
  • AIM: To compare programs of chemotherapy used in adult Berkitt-like lymphoma (ABLL); to assess efficacy and toxicity of the protocol AblL-M-04.
  • ABLL stage I, II, III and IV was diagnosed in 3, 5, 8 and 15 patients, respectively.
  • 10 patients had diffuse large B-cell lymphoma.
  • The modified protocol ABLL-M-04 of intensive short-term therapy included 10 patients, 2 of them pretreated.
  • RESULTS: Of 10 patients given CHOP or CHOP-like courses 9 were resistant to therapy, 2 died of rapid progression, 7 were converted to the program therapy.
  • Six patients died: 4 of progression, 2 of chemotherapy complications.
  • BLL-M-04 therapy was made in 9 patients: 7 patients persisted on the first remission, 2 patients died of chemotherapy complications.
  • Overall duration of the treatment was 3-3.5 months.
  • CHOP therapy cannot be recommended for patients with ABLL because of poor efficacy (all the CHOP patients died).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prednisone / therapeutic use. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116910.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CHOP protocol; PVDA protocol; non-Hodgkin's lymphoma protocol 8503
  •  go-up   go-down


98. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol; 2002 Feb 01;20(3):630-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.
  • PURPOSE: To provide more mature data on the efficacy and complications of a brief, dose-intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally extensive and advanced-stage Hodgkin's disease.
  • PATIENTS AND METHODS: One hundred forty-two patients with stage III or IV or locally extensive mediastinal stage I or II Hodgkin's disease received Stanford V chemotherapy for 12 weeks followed by 36-Gy RT to initial sites of bulky (> or =5 cm) or macroscopic splenic disease.
  • Late effects of treatment were recorded in follow-up.
  • No patient progressed during treatment, and there were no treatment-related deaths.
  • To date, there have been 42 pregnancies after treatment.
  • CONCLUSION: These data confirm our preliminary report that Stanford V chemotherapy with RT to bulky disease sites is highly effective in locally extensive and advanced Hodgkin's disease.
  • It is most important to compare this approach with standard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy in the ongoing intergroup trial (E2496) to determine whether Stanford V with or without RT represents a therapeutic advance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Pregnancy. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2002 Feb 1;20(3):607-9 [11821436.001]
  • (PMID = 11821442.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2RO1 CA56060
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


99. Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, Provencio M, de Lafontan B, de la Rochefordiere A, Cellai E, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy JM, Mignotte H, Velten M: Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol; 2001 Jun;59(3):247-55
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases.
  • PURPOSE: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods.
  • MATERIALS AND METHODS: In a retrospective multicentric analysis, 117 women and two men treated for HD subsequently developed 133 BCs.
  • The median age at diagnosis of HD was 24 years.
  • The HD stages were stage I in 25 cases (21%), stage II in 70 cases (59%), stage III in 13 cases (11%), stage IV in six cases (5%) and not specified in five cases (4%).
  • Radiotherapy (RT) was used alone in 74 patients (63%) and combined modalities with chemotherapy (CT) was used in 43 patients (37%).
  • Sixteen patients (12%) developed isolated local recurrence.
  • Thirty-nine patients (31.7%) developed metastases and 34 died; 38 are in complete remission whereas five died of intercurrent disease.
  • The 5-year disease-specific survival rate was 65.1%.
  • The 5-year disease-specific survival rates for the pN0, pN1-3 and pN>3 groups were 91, 66 and 15%, respectively (P<0.0001), and 100, 88, and 64% for the TIS, T1 and T2.
  • These secondary BC are of two types: a large number of aggressive tumours with a very unfavourable prognosis (especially in the case of pN>3 and/or T3T4), and many tumours with a 'slow spreading' such as DCIS and microinvasive lesions.
  • These lesions developed especially in patients treated exclusively by RT.
  • CONCLUSIONS: The young women and girls treated for HD should be carefully monitored in the long-term by clinical examination, mammography and ultrasonography.
  • Subsequent mammographies should be performed every 2 years or each year, depending on the characteristics of the breast tissue (e.g. density) and especially in the case of an association with other BC risk factors.
  • This screening seems of importance due to excellent prognosis in our T(1S)T(1) groups, and the possibility of offering these young women a conservative treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / etiology. Breast Neoplasms, Male / etiology. Hodgkin Disease / complications. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Confidence Intervals. Female. Follow-Up Studies. Humans. Italy / epidemiology. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Prognosis. Retrospective Studies. Risk Factors. Spain / epidemiology. Survival Analysis. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11369065.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


100. Rao S, Watkins D, Cunningham D, Dunlop D, Johnson P, Selby P, Hancock BW, Fegan C, Culligan D, Schey S, Morris TC, Lissitchkov T, Oliver JW, Holmlund JT: Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann Oncol; 2004 Sep;15(9):1413-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
  • BACKGROUND: The purpose of this study was to assess the efficacy and safety of ISIS 3521, an antisense phosphorothioate oligonucleotide to protein kinase C alpha in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL).
  • Histological subtypes were low-grade follicular lymphoma (n = 22) and B-cell small lymphocytic lymphoma (n = 4).
  • Twenty-one (81%) had stage III/IV disease.
  • The median number of previous lines of chemotherapy was two (range one to six).
  • Ten patients had stable disease.
  • There may be a potential role for this agent in combination with conventional chemotherapy for advanced low-grade lymphoma, and further trials are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15319248.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides, Antisense; 0 / Thionucleotides; 151879-73-1 / ISIS 3521; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha
  •  go-up   go-down






Advertisement